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There is a theory which states that if ever anyone discovers exactly what the 
Universe is for and why it is here, it will instantly disappear and be replaced 
by something even more bizarre and inexplicable 
There is another theory which states that this has already happened 
― Douglas Adams (1952–2001), from the book:  
The restaurant at the end of the universe 
 
If the Lord Almighty had consulted me before embarking upon creation, I 
should have recommended something simpler 
― Alfonso X (1221–1284), also called  
Alfonso el sabio (the wise) 
 Growth hormone and the heart in children 
Anders Nygren 
Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden 
ABSTRACT 
Background and Aims: The fact that growth hormone (GH) influences cardiovascular structure and 
function is well established through both human and animal studies. Despite being secreted in a 
pulsatile fashion, only the impact of peak GH concentrations on cardiac parameters has previously 
been reported, and the time-dependency of cardiovascular effects during GH treatment has not been 
detailed. The aims of this pediatric study were (i) to establish the expression of GH-receptor (GH-R) 
and insulin-like growth factor I (IGF-I) mRNA locally in the heart in children of different ages, (ii) 
to study in detail the relationship between the heart and endogenous GH secretion pattern, (iii) to 
study the cardiovascular effects of GH treatment and (iv) to examine organ/tissue-specific responses 
to GH. 
Patients & Methods: Two trials were conducted. In the first, a cardiac biopsy was taken from 18 
children undergoing heart surgery. GH-R and IGF-I mRNA were quantified by real-time polymerase 
chain reaction. In the second trial, 153 short prepubertal children were randomized to receive either a 
standard or an individualized GH dose. Echocardiography, blood pressure measurements and 
electrocardiography were performed at study start, and after 3 months, 1 year and 2 years of GH 
treatment.  
Results: GH-R and IGF-I mRNA was found in all children studied. There was a significant 
relationship between their relative amounts (r=0.75, p<0.001), and body mass index was correlated 
with the relative expression of both genes (r=0.59, p=0.01 and r=0.50, p=0.04 respectively). Cardiac 
dimensions were not correlated with peak endogenous GH concentration but were negatively 
correlated with GH trough levels (r= –0.41, p<0.001) and positively correlated with GH secretion 
rate above baseline level (r=0.44, p<0.001). During treatment, a biphasic, time-dependent, cardiac 
response was seen. Initially, there was an increase in both standard deviation scores (SDS) for left 
ventricular (LV) diameter in diastole SDS (95% confidence interval (CI) for the increase in SDS 
from baseline to 3 months (ΔLVDdSDS0–3m): 0.05 to 0.36) and LV wall thickness, exemplified by 
septal thickness (ΔIVDdSDS0–3m: 95% CI 0.08 to 0.54). At 2 years, wall thickness returned to baseline 
values (ΔIVDdSDS0–24m: 95% CI -0.41 to 0.06) but LV diameter remained increased (ΔLVDdSDS0–24m: 
95% CI 0.19 to 0.47). The heart was also found to be more responsive than both skeletal muscle and 
bone tissue to GH treatment. The dose resulting in a 50% response (ED50%) was as low as 33 
µg/kg/d (90% confidence bounds: 24–38 µg/kg/d)) for LVDd compared with an ED50% of 51 (47–
56) µg/kg/d for longitudinal growth and  57 (52–65) µg/kg/d for IGF-I. 
Conclusion: With the presence of local GH-R and high sensitivity of the heart to GH, cardiac tissue 
is a primary target for GH. The GH trough levels seem to be of greater importance for cardiac 
dimensions than the peak GH concentrations, and the response to GH treatment is time-dependent 
and differs between LV wall thickness and LV diameter. This demonstrates that GH regulation of 
cardiovascular variables is more complex than previously demonstrated. 
Keywords: Growth hormone secretion pattern, cardiovascular dimensions, Growth hormone 
treatment 
ISBN: 978-91-628-8552-6  
 SAMMANFATTNING 
Bakgrund: Både patienter med över- och underproduktion av tillväxthormon 
(GH) har förändringar i hjärtats struktur och funktion. Avhandlingens syfte var att 
närmare undersöka hur GH påverkar hjärtat hos växande barn. 
Metod: Två projekt genomfördes. I det ena togs biopsier/bitar från hjärtat i 
samband med planerad hjärtkirurgi från arton barn. I dessa bitar undersöktes hur 
mycket mRNA som producerades för GH receptorn (GH-R) och IGF-I. mRNA är 
ett mellansteg från genen i cellkärnan till färdig produkt. I det andra projektet 
undersöktes 153 korta barn före puberteten. De genomgick dels omfattande 
utredningar om hur GH insöndras och dels undersöktes hur deras hjärta reagerade 
på GH behandling i olika doser.  
Resultat: mRNA för GH-R och IGF-I kunde påvisas i hjärtvävnad från samtliga 
undersökta barn. Ju mer GH-R mRNA vävnaden innehöll desto mer IGF-I mRNA 
fanns det i den. Smalare barn (lägre BMI) hade mindre GH-R och IGF-I i hjärtat. 
Insöndring av GH sker pulsatilt med flera toppar per dygn och mellanliggande 
dalar. GH nivåerna mellan topparna visade sig vara viktigare för hur stort hjärtat 
var än höjden på topparna. Ingen skillnad i hjärtundersökningarna mellan barn 
med allvarlig GH brist och mindre uttalad GH brist kunde påvisas. Vid behandling 
med GH sågs först en snabb ökning av hjärtats diameter och hjärtväggens tjocklek. 
Efter två års behandling hade väggtjockleken återgått till de ursprungliga 
förväntade värdena, medan kammarväggens diameter fortfarande var ökad. 
Genom att studera den dos som behövde ges för att olika vävnader i kroppen 
skulle reagera påvisades att hjärtats tillväxt var mer känslig än tex längdtillväxt 
och ökning av IGF-I värdena. 
Sammanfattning: Det finns receptorer för GH i hjärtat vilket gör direkta effekter 
möjliga. Hos korta barn, före puberteten, påverkas hjärtat mer av nivåerna av GH 
mellan topparna än höjden på topparna, som man sedan tidigare vet optimerar 
längdtillväxten. Hjärtat är ett av de känsligaste organen för GH behandling och 
reagerar snabbt med ökad storlek och tjocklek. Efter två års behandling är endast 
hjärtats storlek ökad.  
Betydelse: Avhandlingen visar hur viktigt det är att framtida forskning av GHs 
effekter på hjärtat tar hänsyn till det pulsatila insöndringsmönstret. Den visar 
också att olika delar av hjärtat reagerar olika beroende på hur länge hjärtat utsätts 
för behandling med GH. Detta ger en förståelse för vilka grupper med dålig 
hjärtfunktion som skulle kunna ha glädje av GH behandling i framtiden. 
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∆ Change 
AITT Arginine–insulin tolerance test  
AL Area–length 
ALP Alkaline phosphatase 
ALS Acid labile subunit 
Ao Aortic diameter 
AreaIn Inner left ventricular area 
AreaOut Outer left ventricular area 
ASD Atrial septal defect 
AUCb Area under the curve above baseline level 
AUCt Total area under the curve 
avPeak Average peak value above the zero-line 
BMC Bone mineral content 
BMI Body mass index 
BP Blood pressure 
BSA Body surface area 
Ca2+ Calcium 
cDNA Complementary deoxyribonucleic acid 
CI Confidence interval 
CO Cardiac output 
CoA Coarctation of the aorta 
CV Coefficient of variation 
Da Dalton 
DELFIA Dissociation-enhanced lanthanide fluorescence immunoassay 
DXA Dual-energy X-ray absorptiometry  
DILV Double inlet left ventricle 
ECD Extra cellular domain 
ECG Electrocardiography 
ECW Extracellular water 
ED50% Effective GH dose predicted to result in 50% change effect 
EF Ejection fraction 
ERK Extracellular signal-regulated kinase 
ESS End systolic strain 
ET Ejection time 
F female 
FS Fractional shortening 
GH Growth hormone 
GHb Growth hormone  secretion rate above baseline level 
GHBP Growth hormone-binding protein 
GHD Growth hormone deficiency 
GHI Growth hormone insensitivity 
GHmax Maximum GH peak 
GH-R Growth hormone receptor 
GHRH Growth hormone-releasing hormone 
GHt Total growth hormone secretion rate 
HOMA Homeostasis model assessment 
IGFBP Insulin-like growth factor-binding protein 
IGF-I Insulin-like growth factor-I 
  
IGF1R Insulin like growth factor-I receptor 
inv Inverted 
IRP International reference preparation 
ISS Idiopathic short stature 
IVSd Interventricular septal thickness in diastole 
JAK2 Janus (tyrosine) kinase 2 
Lasso Least absolute shrinkage and selection operator 
ln Natural logarithm 
LST Lean soft tissue 
LV Left ventricular 
LVDd Left ventricular diameter in diastole 
LVDs Left ventricular diameter in systole 
LVPWd Left ventricular posterior wall in diastole 
LVVd Left ventricular volume in diastole 
LVVs Left ventricular volume in systole 
M male 
MAPK Mitogen-activated protein kinases 
MM M-mode 
MPH Mid-parental height 
mRNA Messenger ribonucleotide acid 
mVCFc Corrected mean velocity of circumferential shortening 
n Number 
ns Not significant 
PAPVD Partial anomalous pulmonary venous drainage 
PCA Principal component analysis 
PEP Pre-ejection period 
PHT Pulmonary hypertension 
RA Right atrium 
Ras Rat sarcoma 
rtPCR Real-time polymerase chain reaction 
RV Right ventricle 
SD Standard deviation 
SDS Standard deviation score 
SGA Small for gestational age 
sq Square root 
Src Sarcoma 
SMR Standardized mortality ratio 
SS Somatostatin 
SSI Systolic strain index 
STAT5 Signal transduction and activators of transcription 
SV Stroke volume 
TA Tricuspid atresia 
TGA Transposition of the great arteries 
TMD Trans membrane domain 
ToF Tetralogy of Fallot 
TrS Tracheal stenosis 
Truncus Truncus arteriosus communis type II 
UVH Univentricular heart 
VO2max Maximal oxygen consumption 
VSD Ventricular septal defect 
VTI Velocity time integral 
  
 
  
1 INTRODUCTION AND AIMS 
The first association between growth hormone (GH) and the heart was observed in 
studies of patients with GH hypersecretion. Before the discovery of pituitary GH, 
the term acromegaly was suggested to describe this condition in 1886 by Pierre 
Marie1. Huchard was the first to describe cardiovascular changes in these patients 
in 18952 and, as early as 1912, Cushing postulated that a ”Hormone of growth” 
was present in the pituitary gland. He was also one of the first to describe pituitary 
enlargement in acromegalic patients3. It was not until 1944 that Li and Evans 
isolated and described pituitary GH4. In 1952 and 1954, Beznak published studies 
on rats with experimental aortic constriction that showed GH to be of importance 
in maintaining normal hypertrophic response5-7. Following these discoveries, there 
were a few decades during which there was little research activity in this area. 
Interest in the role of GH in the regulation of cardiovascular structure and function 
then increased substantially during the last 25 years, most likely due to the ready 
availability of GH produced by recombinant techniques from 1985. The 
cardiovascular effects of GH hypersecretion, GH deficiency (GHD) and GH 
treatment have now been studied in both animal models and humans8. In the 
pediatric age group, studies have mainly focused on the cardiovascular effects 
during GH treatment of short stature, with the first study being reported as late as 
19919. In 1999, when the current project was planned, there were only a few 
studies available, and these had yielded varying results varying results9-17. Until 
now, there has been no published information on the importance of endogenous 
GH secretion pattern in the regulation of cardiovascular structure and function in 
humans.  
1.1 Aims 
The overall aim of this thesis was to increase knowledge of the effects of GH on 
the heart in children, both in terms of the effects of endogenous secretion and of 
administered GH. More specifically: 
• to study whether GH receptor (GH-R) mRNA and insulin-like growth 
factor (IGF-I) mRNA are expressed in the heart in children 
• to study the association between endogenous GH secretion pattern and the 
heart in children 
• to study the cardiovascular effects of GH treatment in children 
• to study whether the heart is more or less sensitive to GH treatment than 
other organs. 
 2 BACKGROUND 
The purpose of this section is to give the relevant background information 
necessary to enable critical evaluation of the thesis. Current knowledge of GH and 
the heart in children will be reviewed in the Discussion section. 
2.1 Growth hormone and insulin-like growth 
factor-I axis 
2.1.1 Growth hormone 
GH is a protein hormone that consists of several isoforms. On chromosome 17q 
there are two GH genes. GH1 or GH-N is expressed in the pituitary gland and 
GH2 or GH-V is expressed in the placenta. Originating from GH-N, the most 
abundant form of GH is a 191 amino acid single-chain protein with a molecular 
weight of 22'129 Dalton (Da), also called 22K-GH. By alternative mRNA splicing, 
the second most common GH isoform is a 20'274 Da, 176 amino acid-long protein 
(20K-GH). In addition to a third isoform, 17.5K-GH, GH is also found in 
deaminated forms, N-acylated forms, glycosylated forms, dimeric forms and 
oligomeric forms (up to pentameric)18. In the pituitary gland, the majority of GH is 
the monomeric 22K-GH form (55%), with only a small proportion being the 
monomeric 20K-GH form (6%). Following a secretory pulse from the 
somatotrophic cells in the anterior pituitary, about 50% of 22K-GH and 25% of 
20K-GH becomes bound to a high-affinity GH-binding protein (GHBP), and 5–
8% and 50%, respectively, to a low-affinity GHBP, an α2-macroglobulin19. The 
half-life of 22K-GH is significantly shorter than the half-life of 20K-GH; as a 
result, 20K-GH is relatively more abundant during GH troughs18. Although further 
research is needed on the different properties of the GH isoforms, it has been 
suggested that an increased proportion of GH forms other than 22K-GH might 
impair growth in children20. GH secretion from the anterior pituitary is stimulated 
mainly by GH releasing hormone (GHRH) and inhibited by somatostatin. Both of 
these hormones are secreted from the hypothalamus in a pulsatile manner21. GH 
release is also stimulated by ghrelin, a GH secretagogue, that is mainly produced 
in the stomach, and to a lesser degree in other organs22. Receptors for ghrelin are 
found in the heart in addition to the pituitary gland. 
2.1.2 Growth hormone receptors 
GH-Rs are present to various extents in different organs, being most abundant in 
the liver followed by the heart (in the rat)23. The GH-R is a, so called, 620-residue 
glycosylated class 1 cytokine receptor with two β-sandwich modules, a 
  
transmembrane domain (TMD) and a cytoplasmatic box 1 sequence interacting 
with a box 2 sequence, enabling binding to Janus (tyrosine) kinase 2 (JAK2)24. 
The extracellular domain (ECD) of the GH-R is similar to the high affinity 
GHBP25. Two GH-R units are dimerized at the TMD and subsequent binding of 
GH to the ECD results in rotation and shift of the subunits leading to the activation 
of JAK224. JAK2 phosphorylates signal transduction and activators of transcription 
5 (STAT5) which forms a dimer that regulates gene expression. Other signaling 
pathways are also activated in parallel. For example, a sarcoma (Src) family kinase 
activates the Ras (rat sarcoma) signaling pathway, probably through activation of 
phospholipase Cγ which increases cytoplasmatic calcium (Ca2+). Activation of this 
pathway subsequently activates mitogen-activated protein kinases (MAPK) and 
the extracellular signal-regulated kinase (ERK), that participate in the regulation of 
gene expression24, 26 (Figure 1). 
 
Figure 1. GH-R and IGF1R signaling pathway at a glance. See Subchapter 2.1 for 
abbreviations and a brief review.   
  
2.1.3 Insulin-like growth factor and associated binding 
proteins 
IGFs are expressed after activation of the GH-R. The signaling pathway involved 
is of equal complexity to the one for GH. In brief, the system includes two ligands, 
IGF-I (the major form in postnatal life) and IGF-II (important for fetal growth), at 
least four receptors (IGF1R having the highest affinity for IGF-I)27. In addition 
there are six IGF-binding proteins (IGFBPs), the most abundant being IGFBP328, 
and the acid-labile subunit (ALS). IGFs have mitogenic and anti-apoptotic effects 
through post-receptor effects utilizing several signaling cascades (some of which 
are also utilized by the GH-R)28. IGF-I increases the contractility of the 
cardiomyocyte29. The mechanism responsible for this is not entirely clear, but 
calcium handling seems to be of importance, and there is evidence of increased 
calcium handling in the short term30 and also a change in myosin isoforms31. IGF-I 
also acts as a vasodilator, most likely through direct nitric oxide-releasing 
effects32. 
2.1.4 Growth hormone secretion pattern 
GH is secreted from the pituitary gland in a highly pulsatile fashion33 (Figure 2). 
This pulsatility is maintained mainly as a result of regulation by the stimulating 
GHRH and the inhibiting somatostatin secreted from the hypothalamus. GH 
secretion is modified by negative feedback both from IGF-I and GH34, 35 (Figure 
3). 
Figure 2. Example of 24-hour GH secretion measurements analyzed by the PULSAR 
program. Details are given in the Patients and methods section. 
  
The GH secretion pattern in rats is sexually dimorphic. Male rats have high GH 
peaks every 3 hours with low trough levels in-between33, whereas female rats have 
a higher baseline GH level and lower, more irregular, peaks. Injecting 
Somatostatin into female rats every 3 hours results in a more male-like GH 
secretion pattern36. Moreover, the sexually dimorphic GH pattern corresponds to 
differences in expression of the hepatic enzyme carbonic anhydras-III36. Other 
evidence for the importance of the pulsatility of GH from studies in rats is that 
injection of GH seems to acutely down-regulate the GH-R37, that intermittent 
administration of GH increases IGF-I more than higher daily doses given as a 
continuous infusion, and that continuous infusion upregulates GH-Rs in the liver38.  
 
Figure 3. Possible sites of action for the GH/IGF-I system and GH secretagogues (green 
lines). Red lines indicate direct or indirect inhibition of GH secretion and blue lines 
indicate direct or indirect stimulation. See chapter 2.1 for abbreviations and details. 
 
 In humans it has been shown that daily injection of GH in children with GHD 
results in better growth than if the same weekly dose were given in three injections 
during a week39, that high GH peaks are related to a higher growth velocity, and 
that children growing at the slowest rate had low GH peaks and high trough GH 
levels40. During puberty there are several GH peaks of greater amplitude both day 
and night41, 42. Spontaneous GH secretion can be evaluated using the PULSAR 
program in both research and clinical settings43, 44. This program defines the 
different variables that are studied in this thesis consistently and in a semi 
objective manner (Figure 2). 
2.1.5 Growth hormone sensitivity 
The effects of GH depend not only on the actual level of GH secretion, but also on 
peripheral tissue sensitivity to GH, as well as the complicated interactions 
discussed above. In Laron syndrome there is a defect in the GH-R that arises due 
to a variety of different gene mutations. As a result, children with Laron syndrome 
have short stature despite high serum levels of GH45. This condition is a typical 
form of GH insensitivity (GHI). Less extreme forms of GHI can be observed in 
children with short stature who have low growth velocity but may have varying 
levels of GH secretion, ranging from normal to severely impaired46.  
 
Figure 4. Principal sketch of the relationship between GH secretion and GH sensitivity for 
different conditions. Children with Laron syndrome (GHI), ISS and GHD are short 
compared with peers of equal age. 
  
By convention, the adequacy of GH secretion is determined based on peak GH 
concentrations following two stimulation tests47. GHD is diagnosed based on a 
predetermined cut-off point; however, it is well recognized that the value used is 
largely arbitrary and that the precise cut-off value has changed with increased 
availability of exogenous GH48, 49. Children with short stature and maximum GH 
secretion above the agreed cut-off are traditionally considered as having idiopathic 
short stature 50. This group is starting to be better characterized, with a growing 
number showing mutation in the GH-R or defects at the post-receptor level51, 52. 
Figure 4 shows the relation between GH secretion and sensitivity in GHD, ISS and 
Laron syndrome (referred to as GHI). 
2.1.6 Growth hormone and statural growth 
GH is important for the maintenance of somatic growth during the childhood 
period and well into adult life. During the childhood period, GH acts dose 
dependently and seems to be the most important hormone in this context. During 
juvenility, adrenergic hormones modulate the effects of GH and during puberty 
and adolescence, gonadal hormones have an additional impact on growth53. During 
postnatal life and during all growth periods, thyroid hormone and cortisol have 
permissive effects. 
 
2.2 Age-dependent changes in the cardiovascular 
system 
The fact that cardiovascular dimensions and function change with age is obvious. 
A larger body requires a larger heart. Although several cross-sectional studies of 
cardiovascular structure and function have been published, our knowledge of the 
regulation of cardiovascular changes is limited. To put the changes seen during 
GH treatment into context, I will briefly review the normal development of the 
heart, focusing on the childhood period where longitudinal growth is most 
dependent on the GH/IGF-I axis53, 54. 
GH/IGF-I axis: 
GH is secreted from the pituitary gland in a pulsatile fashion. GH acts both 
directly on target tissues and through IGF-I produced locally and in the liver.  
The balance between secretion and peripheral sensitivity determines GH effects. 
During the childhood period, GH is the main regulator of somatic growth. 
 2.2.1 Blood pressure 
During childhood and throughout puberty there is a slow but steady increase in 
both systolic and diastolic blood pressure (BP)55. Average systolic/diastolic BP is 
about 91/46 mmHg at 1 year of age and 102/63 mmHg at 10 years of age, with no 
major differences reported between boys and girls. By 17 years of age, BP is 
slightly higher in boys than in girls (118/64 vs. 110/62 mmHg, respectively) and 
racial differences have also been reported56, 57. 
2.2.2 Time intervals in the electrocardiogram 
Heart rate declines with increasing age. Between 1 and 3 years of age, heart rate is 
slightly higher in girls than in boys (median 128 bpm vs. 119 bpm, respectively). 
By 5 to 8 years of age, heart rate is the same in both genders (median 88 bpm) and 
no big differences are reported during puberty (76 bpm in girls, 73 bpm in boys)58. 
The PR interval increases with age and does not differ between genders. QRS 
duration also increases with age, but the median duration is slightly longer in boys 
than in girls. The QT interval increases as heart rate decreases and, thus, QT 
intervals increase with age during childhood. When corrected using the Bazett 
formula, QT interval remains stable with age58.  
2.2.3 Left ventricular dimensions 
Although LV mass is not commonly assessed in the clinical setting of pediatric 
cardiology, several reports on LV mass in normal children have been published. In 
the majority of studies, echocardiography was used to estimate LV mass and a 
couple of methods have been evaluated59, 60. Up to 12 years of age there were no 
significant differences in LV mass between girls and boys, probably reflecting 
similarities in height and weight61. After 12 years of age, LV mass is greater in 
boys than in girls, even when indexed to body surface area (BSA)61. Different 
methods have been used to normalize LV mass for body size. As adjusting for 
BSA introduces an artificial relationship with body size, indexing by dividing with 
height to the allometric power of 2.7 has been suggested62. However, at heights 
less than 140 cm, this index has a significant negative relationship with height and 
LV-mass-for-height centile curves have been shown to be superior to LV 
mass/height2.7 in normalizing for body size in shorter children63 (Figure 5). LV 
diameter and wall thickness have the same relationship to body size as LV mass. 
This is not surprising because these variables are usually used for the calculation 
of LV mass. They are often normalized by the use of standard deviation scores 
(SDS)64.  
 
 
  
Figure 5. Example of the relationship between LV mass (g) and height (cm) and the 
overcorrection that occurs when dividing LV mass by height to the allometric power of 2.7. 
2.2.4 Cardiac systolic function 
The fraction of blood ejected from the LV with each beat, the ejection fraction 
(EF), varies little over time. Stroke volume (SV) and the volume ejected during 
one minute, the cardiac output (CO) however varies with body size and age, 
increasing in a non-linear fashion65.  
2.2.5 Cardiac diastolic function 
The general notion is that the diastolic function deteriorates with age. This is not 
evident in children. Measurements of LV filling pattern, as an estimate of diastolic 
function, change during childhood in a way that in adult life would constitute an 
improvement66. As an example, the mitral E/A ratio increases from a median of 
~1.2 at a BSA of 0.5 m2 to ~1.7 at a BSA of 0.8 m2, thereafter, remaining stable 
during childhood66. 
Age-dependent changes in the cardiovascular system: 
LV dimensions increase with age. The resulting increase in SV is followed by a 
reduction in heart rate. LV contractility seems to be independent of longitudinal 
growth and during the childhood and juvenile period, parameters of diastolic 
function improve. Although the relationship between body size and cardiac mass 
has been well established in cross sectional studies, there is no published 
information on cardiac growth velocity during the different  
phases of longitudinal growth. 
 3 PATIENTS AND METHODS 
3.1 Study design 
This thesis is based on two projects. The first is called the “Heart biopsy” study 
and the second the “GH-dose catch-up” study. 
3.1.1 Heart biopsy study 
Children scheduled for open heart surgery and their parents were approached 
regarding participation in the study. If consent was given, a biopsy of cardiac 
tissue was taken at the time of surgery. Biopsies were analyzed using real-time 
polymerase chain reaction (rtPCR), as described in detail below. Hormonal 
evaluations, dual-energy X-ray absorptiometry (DXA) scans and study protocol-
specific echocardiograms were not conducted in these children. 
Table 1. Inclusion and exclusion criteria in the GH-dose catch-up study 
Inclusion criteria 
Prepubertal 
Girls: 3–10 yrs 
Boys 3–11 yrs 
Short 
HeightSDS< –2 SDS or  
Growth velocity < –1 SDS 
Shorter than genetic potential 
MPHSDS< –1 SDS 
Not severely premature 
GA > 30 weeks 
Additional requirements 
Height and weight data 
At birth, and at 1 and 2 years of age 
1-year pretreatment 
Two measurements during the pretreatment year 
Exclusion criteria 
Chronic illness 
Clinical syndrome 
Extremely underweight or obese 
Catch-up growth during pretreatment year 
Tall parents (MPHSDS>1.5 SDS) 
 
 
  
3.1.2 GH-dose catch-up study 
This thesis concerns the cardiovascular assessment of children included in a large, 
longitudinal, prospective, multicenter study (study number TRN 98-0198-003). 
The main objective of this trial was to determine whether catch-up growth in 
individual children with isolated GHD or ISS could be targeted using 
individualized GH doses rather than a standard dose. Five Swedish centers 
participated in the study: Gothenburg, Halmstad, Malmö, Umeå and Uppsala. The 
children were required to be prepubertal at the start of the study, and free from 
concomitant disorders. Table 1 summarizes the inclusion and exclusion criteria. A 
maximum of one-third of the children were allowed to have ISS as determined 
based on the maximum GH peak (GHmax) obtained on the arginine–insulin 
tolerance test (AITT) which was the gold standard method for diagnosing GHD at 
the start of the study. The children were randomized in a 1:2 fashion to receive 
either a standard GH dose (43 μg/kg/d) or an individualized GH dose based on GH 
responsiveness as estimated by a validated prediction model67.  
Table 2. Schedule for dose selection in the group receiving individualized GH 
doses. 
Predicted ΔHeightSDS 
after 2 years 
Predicted distance from MPHSDS after 2 years 
< –1.2 –1.2 to –0.8 –0.8 to –0.5 –0.5 to +0.5 > +0.5 
< 1.2 100 66 50 33 17 
1.2 to 1.8 66 50 40 33 17 
> 1.8 50 33 33 17 17 
The selected dose is shown in μg/kg/d. The predicted ΔHeightSDS and predicted distance 
from MPHSDS after 2 years are based on postulated treatment with a GH dose of 33 
μg/kg/d. Reproduced from Kriström et al.46. 
By using pretreatment data, the model accurately predicts the 2-year growth 
response to a GH dose of 33 μg/kg/d with an error of only 0.28 SDS of the 
residual. The predicted growth response was used, together with the heightSDS 
difference to mid-parental height (MPH) SDS (diffMPHSDS) for dose-selection in 
the individualized group within the range of 17–100 μg/kg/d. The target was to 
reach MPHSDS after 2 years of treatment (i.e. the lower the GH responsiveness and 
the greater the distance to MPHSDS, the higher the GH dose given). The mean GH 
dose used in this group was 49 μg/kg/d (see Table 2). 
3.2 Ethical considerations 
3.2.1 Heart biopsy study 
There were no potential benefits for the individual child from participating in the 
heart biopsy study. The researcher approaching the family was not involved in the 
 clinical management of the patients. The technique for taking biopsies was 
considered safe based on previous publications and the experience of the thoracic 
surgeons performing the scheduled cardiac surgery68, 69. The protocol was 
approved by the ethical board of the University of Gothenburg (registration 
number Ö184-01 with final decision 14-Jun-2001) and conducted in accordance 
with the declaration of Helsinki (initial statement and amendments found on the 
homepage of the World Medical Association, www.wma.net). Written informed 
consent was obtained from all parents and from children where possible. 
3.2.2 GH-dose catch-up study 
At the start of the trial, the indication for GH treatment in short normal children 
was GHD, as estimated by two stimulation tests. The potential benefit for children 
participating in the study was that treatment could be undertaken even if they were 
categorized as non-GH-deficient. In the standard clinical setting, the medical 
investigation prior to starting treatment is extensive. Additional tests were 
conducted in children included in this study which could be considered a 
disadvantage. GH treatment is considered to have a good safety profile at 
recommended doses. The dose for the fixed-dose group was slightly higher than 
the standard dose used in Sweden at the start of the trial. Higher GH doses had, 
however, been used in other groups of children without significant problems. The 
dose used was also the standard dose used in the USA at the time. The children 
randomized to receive an individualized dose could be treated with either lower or 
significantly higher doses than the standard dose. The individualized dose was, 
however, considered to be “biologically” similar to the standard dose. Adverse 
events were monitored carefully throughout the study. The protocol was approved 
by the ethics boards of the University of Gothenburg (for Gothenburg and 
Halmstad), Umeå, Uppsala, and Lund (registration number L 553-98 with final 
decision 2-Jun-1999), and by the Medical Product Agency of Sweden. Written 
informed consent was obtained from all parents and from children where possible. 
The trial was performed in accordance with the Declaration of Helsinki and Good 
Clinical Practice (GCP). 
Study design: 
Two trials were performed. In the "Heart biopsy study", included children had 
cardiac biopsies taken during scheduled open heart surgery. In the "GH-dose 
catch-up study", short prepubertal children were randomized to receive either a 
standard GH dose or an individualized dose based on a validated prediction 
model and taking predicted distance from target height into consideration. The 
studies were approved by the appropriate ethics boards and the Medical Product 
Board of Sweden. The Declaration of Helsinki was honored. 
  
3.3 Methods 
3.3.1 Collection and preparation of biopsies 
During open heart surgery, catheters are used to divert blood from the heart and 
return it to the system circulation after oxygenation. A single transmural right 
auricular biopsy was taken at the time of venous catheterization. Biopsies were 
promptly frozen in liquid nitrogen and stored at –70° C during the sampling 
period. All biopsies were analyzed simultaneously. Management of tissues was 
conducted in a DNA:se free environment. 
3.3.2 Real-time polymerase chain reaction 
During real-time polymerase chain reaction (rtPCR), cDNA is duplicated in the 
presence of a signaling probe. When the concentration of the probe is high enough 
it is detected and the signal intensity increases with increasing amounts of cDNA. 
The more cDNA there is in the initial sample, the 
earlier the signal intensity reaches a set threshold 
(see Figure 6). Primer Express Software 
(Applied Biosystems, Inc. Foster City, 
California, USA; currently Life Technologies, 
Carlsbad, California, USA) was used for the 
design of pairs of primers and probes from the 
human mRNA sequence. Sequences used for 
forward, reverse primer and probe are given in 
Paper I. Primer and probes were designed for 
GH-R and IGF-I mRNA. The primers and 
TaqMan probes were synthesized by Applied 
Biosystems, Inc. Total mRNA was prepared with 
TRIZOL® Reagent (Invitrogen, Carlsbad, 
California, USA, currently Life Technologies, 
Carlsbad, California, USA), using a standard 
protocol.  
 
Figure 6. Schematic illustration of one cycle in a real-
time polymerase chain reaction. Initially the cDNA is 
separated by heating to 95○C. Lowering the 
temperature allows the probe to attach and the primers 
to initiate replication which will cleave the probe 
activating a signaling  unit. The cycle will result in two 
cDNA strands instead of one, and the number of cycles 
needed for the signal to be detected is proportional to 
the initial quantity of cDNA in the sample. 
 After cDNA synthesis, TaqMan One-Step RT-PCR Master Mix Reagents Kit 
(Applied Biosystems, Inc.) was used for rtPCR. As internal standard, 18S rRNA 
was used. Because of interference, multiplex PCR was not possible and GH-R and 
IGF-I were analyzed separately. Amplification and detection were performed 
using the ABI PRISM 7700 Sequence Detector System (Applied Biosystems, 
Inc.). One sample from each patient was analyzed in duplicate. Relative 
expression of mRNA was calculated with the comparative Ct method, and results 
were expressed as multiples of the lowest value. 
3.3.3 Auxology measurements 
Height was measured using a standing Harpenden stadiometer. The mean of three 
measurements was used. Height was converted into SDS using the prepubertal 
childhood component70 of the total reference71. Weight was measured using 
weighing scales with an accuracy of ±0.1 kg. WeightSDS was calculated using the 
reference population from Albertsson-Wikland et al.71. Body mass index (BMI) 
was calculated using the formula BMI = Weight (kg) / Height2 (m2), and converted 
to SDS72. Target height was estimated using MPH in a linear function, as 
previously described73, and using reference data from an earlier cohort born in 
1956, thus taking the secular trend into account74. Body surface area (BSA) was 
calculated using Mosteller’s simple formula BSA =  
( height(cm) x weight(kg) / 3600)0.5.75, 76 
 
3.3.4 Cardiovascular assessment 
Cardiovascular assessments included serial echocardiograms, electrocardiograms 
(ECG) and BP measurements. Examinations were performed before study start, 
after 3 months of treatment, after 1 and 2 years of treatment. Each individual child 
was examined longitudinally by the same cardiologist/sonographer. The 
examinations in Umeå, Uppsala, Halmstad and Lund were performed by one 
pediatric cardiologist at each site. In Gothenburg, the examinations were 
performed by a single experienced sonographer.  
 
Measured variables 
Systolic and diastolic BP was measured in the supine position using a DynaMap 
system. Heart rate, PR interval, QRS duration and corrected QT (QTc) interval 
were automatically measured from the ECG. The following M-mode (MM) 
variables were measured: interventricular septal thickness in diastole (IVSd), LV 
inner diameter in diastole and systole (LVDd/LVDs) and LV posterior wall 
thickness in diastole (LVPWd). From two-dimensional pictures, the diameter of 
the aortic annulus was measured from the parasternal long-axis view. The outer 
  
and inner areas of the left ventricle were measured from the parasternal short-axis 
view at the level of the papillary muscles, and the length of the left ventricle was 
measured from the apical four-chamber view. The flow pattern over the mitral 
valve was recorded using pulsed-wave Doppler.  
Table 3. Formulae for the calculation of cardiac variables 
LV mass by M-mode method (LV mass MM) Ref. 
LV mass MM = 0.8 × 1.04 × (ሾܫܸܵ݀ + ܮܸܦ݀ + ܮܸܹܲ݀ሿଷ− ܮܸܦ݀ଷ) + 0.6 59 
LV volume in diastole (LVVd) 
LVVd = 
7ܮܸܦ݀ଷ
(2.4 + ܮܸܦ݀) 77 
LV volume in systole (LVVs) 
LVVs = 
7ܮܸܦݏଷ
(2.4 + ܮܸܦݏ) 77 
Stroke volume (SV) 
SV = ܮܸܸ݀ − ܮܸܸݏ  
Fractional shortening (FS) 
FS = 
ܮܸܦ݀ − ܮܸܦݏ
ܮܸܦ݀   
Cardiac output by M-mode method (CO MM) 
CO MM = ܸܵ × ℎ݁ܽݎݐ ݎܽݐ݁  
Corrected mean velocity of circumferential shortening (mVCFc) 
mVCFc = 
ܨܵ
ܧܶ √ܴ − ܴ ݀ݑݎܽݐ݅݋݊⁄  78 
Cardiac output by Doppler and 2D method (CO Doppler) 
CO Doppler = ߨ(ܣ݋ݎݐ݅ܿ ݀݅ܽ݉ݐ݁ݎ)ଶ4 × ܸܶܫ × ℎ݁ܽݎݐ ݎܽݐ݁  
LV mass by area–length method (LV mass AL) 
LV mass AL = 
1.055 × 56 × (ܮܸ ܱݑݐ݁ݎ ܽݎ݁ܽ × ሾܮܸ ݈݁݊݃ݐℎ + 1ሿ
− ܮܸ ܫ݊݊݁ݎ ܽݎ݁ܽ × ܮܸ ܮ݁݊݃ݐℎ) 60 
Mitral E/A ratio  
Mitral E/A ratio = 
ܯ݅ݐݎ݈ܽ ܧ ݓܽݒ݁ ݒ݈݁݋ܿ݅ݐݕ
ܯ݅ݐݎ݈ܽ ܣ ݓܽݒ݁ ݒ݈݁݋ܿ݅ݐݕ  
 
 From pulsed wave Doppler in the LV outflow tract, the peak velocity, velocity 
time integral (VTI), ejection time (ET) and pre-ejection period were measured. 
Measurements during three consecutive cardiac cycles were averaged to minimize 
the impact of respiratory variations. Calculation of additional variables was done 
using formulae given in Table 3. 
Normalization of cardiovascular variables for body size 
BP and variables associated with cardiac growth are closely related to height and 
body composition as described in the Background section. As GH treatment 
promotes growth and alters body composition, it is difficult to discern specific 
effects of GH on the heart in growing children. Most variables were therefore 
normalized either by indexing them to body size (BSA or height) or by calculating 
an SDS based on published values. BP was normalized using the formulae 
provided by Rosner et al.56, M-mode measurements using the formula by Lester et 
al.64, LV mass according to M-mode using the formula by Foster et al.63 and LV 
cardiac index using the formula by De Simone et al.65. The references used for the 
SDS of the cardiac variables are summarized in Table 4. QTc was calculated 
according to the formula by Bazett79. 
Table 4. Measured variables and references used for calculation of SDS 
Variable Ref. Children (n) Ages Predictors 
Blood pressure 56 20 225 to  
28 664 per 
subgroup 
1 to 17 yrs Gender 
    HeightSDS 
    Age 
IVSd 64 202 0 to 23 yrs Gender 
LVDd    Age 
LVDs    Height 
LVPWd    Weight 
     Race 
     Heart rate 
LV mass MM 63 440 0 to 21 yrs Height 
 
3.3.5 Laboratory measurements 
GH, IGF-I, IGFBP3 and leptin were analysed at the Göteborg Pediatric Growth 
Research Center (GP-GRC) laboratory (Swedac accredited no.1899)80-82. GH was 
analyzed using a monoclonal assay and international reference preparation (IRP) 
80/505. The detection limit for the kit was 0.03 mU/L. At concentrations of 0.4, 
5.1 and 21.1 mU/L, the intraassay variations (% coefficient of variation (CV)) 
were 5.1, 2.7 and 2.2 %, respectively, and the inter-assay variations (% CV) were 
2.5, 2.1 and 1.4%, respectively. SDS were calculated for IGF-I, IGFBP3 and for 
the IGF-I/IGFBP3-ratio83, 84. Alkaline phosphatase (ALP), fasting insulin and 
  
fasting glucose levels were assessed at the accredited university hospital 
laboratories. Insulin resistance was estimated by homoeostasis model assessment 
(HOMA), using the formula of Matthews et al [(fasting serum insulin × fasting 
plasma glucose)/22.5].85  
3.3.6 GH secretion pattern and rate 
GH secretion was assessed using both the AITT and a 24-hour GH secretion 
profile. The AITT was performed by administering arginine, sequentially followed 
by insulin, as described by Penny et al.86. The highest GH measurement obtained 
during the two provocation tests (GHmaxAITT) was used. The 24-hour GH 
secretion profile was assessed by taking integrated blood samples every 20 
minutes for 24 hours. This method has been described in detail by Albertsson-
Wikland et al43.  GH levels were measured and the results were analyzed by the 
PULSAR program with settings for GH43, 44. The following variables were used: 
maximum peak amplitude (GHmax24h), average peak amplitude (avPeak), total 
area under the curve (AUCt), area under the curve above the baseline level 
(AUCb), baseline GH level, number of peaks, length of peaks.  
Figure 7. Schematic drawing showing the baseline GH level (the GH trough level) and the 
GH secretion rate above baseline level (GHb). 
The measured concentrations of GH during the 24-hour GH secretion profile are 
dependent on both pituitary secretion and plasma clearance. An algorithm for 
estimating the actual pituitary secretion rate has previously been developed 
through single-injection kinetic studies. The formula includes cumulative secretion 
and body mass (weight) and was used to calculate total GH secretion rate (GHt) 
over zero-line and GH secretion rate above the baseline level (GHb), see example 
in Figure 7. 87 
 3.3.7 Classification of GH status 
Initial diagnostic classification of children as having GHD or ISS was made based 
on the results of the AITT which was the gold standard method at the start of the 
study 88. The cut-off value for the diagnosis of classic GHD was a GHmaxAITT of 
<22.6 mU/L (monoclonal dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA)) using IRP 80/505, corresponding to a cut-off value of 
<32 mU/L for a polyclonal assay and to <20mU/L (<10 µg/L) when using 
polyclonal antibodies and IRP 66/12780. Severe GHD was defined as a 
GHmaxAITT of <11.3 mU/L for comparison with data from Capalbo et al. and 
Salerno et al.89, 90. Alternative classification of GHD was done using the GHmax 
from either the 24-hour GH-secretion profile (GHmax24h) or by combining 
GHmax24h with GHmaxAITT. 
3.3.8 Evaluation of GH responsiveness 
Individual GH responsiveness was estimated using a validated model for 
predicting the 1- and 2-year growth response to a standard GH dose (33µg/kg/d)67. 
By using pretreatment data, the residual standard deviation (SD) of the model is 
0.19 SDS for the 1-year growth response and 0.28 SDS for the 2-year growth 
response. The algorithm includes the variables MPHSDS, gender, weightSDS at birth, 
heightSDS at 1 and 2 years of age, ∆heightSDS during the year before GH start, 
heightSDS at GH start, age at GH start and GHmax24h. The predicted growth 
response (∆heightSDS expected after the first and second years on GH treatment) is 
an indirect estimate of individual GH responsiveness for longitudinal growth.  
3.3.9 Measurement of body composition 
Body composition was measured by DXA, using either Lunar DPX-L scanner (GE 
Medical, Madison, WI, USA) or a Lunar Progidy (GE Medical). Each child was 
measured longitudinally using the same settings. DXA assessment results in a 
three-compartment model of the body consisting of fat mass, lean soft tissue (LST) 
mass and bone mineral content (BMC). All analyses were conducted using the 
extended analysis program for total body analysis with pediatric settings. LSTSDS 
was calculated according to Dutch normative data91, 92. 
3.3.10 Control group 
Finding a representative control group with which to compare short prepubertal 
children is not without problem. The children in the study population are all very 
short for age and gender (< –2 SDS). Stratifying a normal control group according 
to age would result in the selected children being significantly taller than the study 
population, whereas stratifying them for height would make them significantly 
younger than the study population. As height seems to be the most important 
factor determining cardiac dimensions, it is usually used for stratification63, 89. 
However, this leaves a question regarding the impact of both age and growth 
  
velocity on cardiac dimensions. The control group in Paper II were drawn from an 
institutional reference population that was under creation. Echocardiographic 
examinations, ECGs and BP measurements from children without heart disease 
were re-analyzed by a single pediatric cardiologist in a retrospective fashion. The 
sample was strictly stratified by height and gender.  
3.4 Statistical considerations 
Distribution 
The distribution of values was assessed in order to select the most informative 
presentation method and to identify the appropriate statistical method. The 
likelihood that a set of data were normally distributed was examined by studying 
frequency histograms and normal probability plots. The data were also tested 
using the Kolmogorov–Smirnov test with Lilliefors correction and the Wilk–
Shapiro test, and finally by calculation of skewness and kurtosis. If normally 
distributed, data were presented as mean ± SD, otherwise data were presented as 
median (25th–75th percentile). In Paper II, median (25th–75th percentile) was used 
for consistency and non-normality was indicated by a double dagger. Parametric 
or non-parametric statistical methods were chosen, as appropriate. 
Transformations 
In the case of multiple linear regressions and principal component analysis (PCA), 
non–normally distributed data were transformed successfully. Weight, LV mass 
MM, CO, mVCFc, mitral E/A ratio, insulin, HOMA and GH responsiveness were 
transformed using the natural logarithm (ln). GHmaxAITT, GHmax24h, avPeak, 
baseline GH level, GHt and GHb were transformed using the square root (sq). 
Leptin was inverted (inv) and presented as a negative inverted value to restore the 
original order (–inv). 
Correction for multiple comparisons 
Performing multiple comparisons between groups will inevitably increase the rate 
of type I error. Correcting for this will on the other hand increase the rate of type II 
error to the extent that important information is lost or hidden. Consequently, data 
were presented without correction. If the effect of multiple comparisons was 
considered important it was pointed out in the results section. 
Comparison between groups 
Comparisons between groups were conducted using independent sample t-tests, 
paired sample t-tests or Mann–Whitney U-tests, as appropriate. A p-value less than 
0.05 was considered statistically significant. 
 Bivariate correlations 
Pearson’s product moment correlation was calculated for normally distributed 
variables. Otherwise Spearman’s rank order correlation was used. 
Linear regression 
The Lasso (Least absolute shrinkage and selection operator) method was used for 
the multiple linear regression analysis, and the models were validated with 
permutation tests. Residuals were required to be normally distributed and data 
were otherwise transformed. 
S-shaped piecewise linear regression and Effective dose at 50% 
effect 
In Paper IV the dose–response relationship was examined for the GH effect on 
different organ systems. To mimic the S-shaped curve often observed in biological 
systems, S-shaped piecewise linear regression models were fitted with GH dose as 
the predictor variable and the Δ-value of the metabolic, cardiac and body 
composition variables as response variables. The piecewise linear regression 
consisted of three parts, a horizontal head and tail and a linear piece in the middle. 
Details are given in Paper IV. The effective GH dose predicted to result in 50% ∆ 
effect (ED50%) was calculated with a 90% confidence interval. A one-way 
analysis of variance (ANOVA) with GH dose as a bounded continuous predictor 
was performed to test the piecewise linear GH effect. A non-parametric 
comparison of group means (robust test of equality of means – Welch test and 
Brown–Forsythe test) was conducted when variances of dependent variables were 
not equal across groups. To examine the influence of the 17 μg/kg/d dose group 
that consisted of only three children, analyses were repeated with these children 
excluded. Only data that were consistently significant were reported.  
Principal component analysis 
PCA is a powerful tool, both for reducing a large set of data and for describing 
complex interactions93. In Paper II, cardiac variables were analyzed together with 
age, heightSDS, weightSDS, GH responsiveness, GH-secretion and metabolic 
variables. In the PCA, extraction was based on Eigenvalue >1. To simplify the 
interpretation of data, loadings were rotated using the Varimax method94. Missing 
data were handled by replacing with the mean. For clarity, a few variables have 
been selected for graphical presentation in this thesis. More detailed results are 
presented in Paper II. Variables at 90° relative to each other are not correlated with 
each other; variables pointing in the same direction are strongly and positively 
correlated with each other, and variables at 180° to each other are strongly and 
negatively correlated with each other. The length of the line and its projection 
against the X or Y axis describes how strong the variable is in the component. The 
percentage of variance explained by the models and different components were 
taken from the rotation sums of square loadings. 
  
Software 
In addition to SPSS 17.0 (SPSS Inc., Chicago, USA), MATLAB version 7.13.0 
(R2011b, The Mathworks, Natick, MA, USA) was used for the calculations. 
  
Methods: 
Cardiac biopsies were analyzed using rtPCR to estimate the relative expression of 
GH-R mRNA and IGF-I mRNA. Children in the GH-dose catch-up study were 
examined using ECG, echocardiography, DXA, and blood pressure, GH secretion 
and metabolic data were also assessed. Great care was taken to use appropriate 
statistical methods. Acknowledging the complexity of these data, advanced 
statistical methods were used in a descriptive manner (referring to PCA, 
 piecewise linear regression and the Lasso method).   
 4 RESULTS 
This section is both a complement to and a summary of the original papers. 
Detailed information is repeated only when needed for clarity or when it provides 
additional information 
4.1 Heart biopsy study – Paper I 
Eighteen children with a variety of cardiac diseases were included in the study. 
One child were put on cardiac bypass because of resection of a tracheal stenosis, 
the rest had scheduled open heart surgery. There was a wide range in ages and 
diagnosis of the children, summarized in Table 5 (for full detail, see Paper I, Table 
1). 
Table 5. Patient characteristics and results in the heart biopsy study 
Group 
Age 
(y) Gender 
Cardiac 
diagnosis 
Length 
(cm) 
Weight 
(kg) 
GH-R 
mRNA 
IGF-I 
mRNA 
Cyanotic 
infants 
0.02 M TGA 55 3.5 2.49 2.36 
0.02 M DILV, TGA, CoA 53.5 3.5 1.45 1.00 
0.12 F TA 51.5 3.44 3.69 5.18 
Infants with 
PHT 
0.06 F Truncus 54 4.04 5.12 6.01 
0.23 M VSD 55 4.05 2.11 7.97 
0.29 F VSD 53.5 3.71 1.02 1.99 
0.35 M VSD 62.5 5.18 2.26 2.03 
Children 
with UVH* 
3.3 F TA 98 16.3 27.36 31.54 
4.1 F TA 95.5 13.3 1.36 1.34 
Volume-
loaded 
RA/RV 
3.2 F PAPVD 99 15.2 11.22 3.24 
3.9 M ASD 102 15 1.00 1.16 
4.0 M PAPVD 110 15.7 1.20 1.50 
5.8 M ASD 123.5 27 5.42 2.95 
Mixed 
group 
0.35 F ToF 69.5 8.56 2.99 4.14 
0.48 M ToF 63 6.6 2.23 1.82 
1.9 F CoA 86 12.3 5.04 7.37 
3.8 M TrS 104 19.3 5.08 5.51 
15.8 M VSD 185 72 7.31 12.67 
GH-R mRNA and IGF-I mRNA are expressed as multiples of the lowest value.  
* Biopsies taken at time of Fontan completion. See abbreviation list for details. 
 
Both GH-R mRNA and IGF-I mRNA were detected in biopsies from all children. 
The relative amounts are displayed in Table 5. Expression of GH-R mRNA and 
IGF-I mRNA was strongly correlated (r=0.75, p<0.001). In Paper I, Figure 1, the 
correlation is shown for all patients. In Figure 8, below, the outlier has been 
excluded and the correlation is still preserved (r=0.71, p<0.001). The correlations 
  
of GH-R and IGF-I mRNA with age, length, weight, BMI, BP, gender and the 
occurrence of cyanosis were also studied. GH-R mRNA correlated positively with 
weightSDS (r=0.65, p=0.004), BMI (r=0.59, p=0.01) and BMISDS (r=0.59, p=0.01). 
IGF-I mRNA only correlated with BMI (r=0.50 p=0.04). No correlations were 
found between GH-R or IGF-I mRNA and age, length, weight, BP, gender or the 
occurrence of cyanosis. 
 
 
 
 
Figure 8. Gene expression is presented as 
multiples of the lowest value. Excluding the 
most extreme outlier, the Spearman rank 
order correlation was still significant (r=0.71, 
p<0.001). 
 
 
4.2 GH-dose catch-up study. Papers II–IV 
A total of 153 children from five pediatric units in Sweden [Gothenburg (n=79), 
Umeå (n=34), Uppsala (n=17), Malmö (n=13) and Halmstad (n=10)] were 
included. At 2 years, 128 children (38 girls) had completed the protocol and 
remained prepubertal, constituting the per-protocol population (Papers III, IV). 
Sixteen children were excluded because they had entered puberty and four because 
of poor compliance with GH injections. One was found to have a cranio-
pharyngioma and one juvenile rheumatoid arthritis. These two patients were from 
Gothenburg and were excluded from the analysis in paper II. An additional three 
children were wrongly included. In addition, data from a child who did not 
Results in the  heart biopsy study: 
GH-R mRNA and IGF-I mRNA were detected in all children studied. The 
relative amounts were correlated with each other (r=0.75, p<0.001). 
Expression of GH-R mRNA was correlated with BMI and BMISDS. Expression of 
IGF-I mRNA was correlated with BMI. 
 undergo baseline cardiac evaluation due to a protocol violation was excluded from 
the analysis in Paper III. The gender of the children who were excluded and the 
reasons for exclusion were comparable between the randomization groups. In 
Paper II, only the pretreatment data of the Gothenburg population were studied to 
avoid inter-observer variability. Inter-observer variability was not considered a 
problem in the longitudinal analysis of data in Paper III and IV, as only changes in 
the individual child over time were studied and each child was examined by a 
single echocardiographer/cardiologist. The study population is summarized in 
Figure 9. 
Figure 9. Summary of the GH-dose catch-up study population. 
 
4.2.1 Comparison between stimulation test and 
spontaneous GH secretion 
Maximum GH concentration 
In the intention to treat population (n=153), there was a weak correlation between 
maximum GH concentration during stimulation test (GHmaxAITT) and maximum 
GH concentration during spontaneous 24-hour GH secretion (GHmax24h) (r=0.30, 
p<0.001, Figure 10). The number of children defined as being severely GH-
deficient, partially GH-deficient or as having ISS will depend on which of the two 
diagnostic methods is being used. Combining them will result in a different 
classification (Table 6). The same was found for the Gothenburg population (see 
Paper II, Figure 1). 
  
Additional information from spontaneous secretion 
As discussed in the Background section, the secretion of GH has a complex 
pulsatile pattern. If only the peak GH concentration is taken into account, a great 
deal of available information will be ignored. This includes the number of peaks, 
the trough GH level and the GH secretion rate.  
Table 6. Number of children in each category depending on method of diagnosis. 
n = 153 Severe GHD <5 µg/L* 
Partial GHD 
5-10 µg/L* 
ISS 
>10 µg/L* 
GHmaxAITT 38 73 42 
GHmax24h 14 50 89 
GHmaxAITT+24h 9 43 101 
* < 5 µg/L corresponds to < 11.3 mU/L, > 10 µg/L corresponds to 
> 22.6 mU/L, adjusted for the standard and antibodies used (see 
paragraph 3.3.7) 
 
 
Figure 10. Correlation between GHmaxAITT and GHmax24h. Dotted lines mark the cut-off 
value below which severe GHD is diagnosed. The area between the dotted and solid lines 
gives the range of values that are considered to warrant a diagnosis of partial GHD. 
 
 Figure 11. Differences in the GH trough level found during spontaneous secretion for two 
children with similar peak GH values. The two children had similar HeightSDS  
(–3.0 SDS and –2.9 SDS, respectively) but LV massSDS differed substantially (–0.2 SDS and 
–2.4 SDS, respectively), with the higher GH trough level being associated with a lower LV 
mass. 
Figure 12. Differences in AUCt found during 24 hours spontaneous profile in two children 
with similar GHmax24h. LV massSDS was similar in these two children (0.1 SDS vs. 0.1 
SDS). 
Figure 11 shows examples of two patients from the GH-dose catch-up study with 
similar GHmax24h and differences in the trough GH levels. Figure 12 shows two 
other patients from the study with, similar GHmax24h but the AUCt is almost 
doubled in the child shown in the left panel (127 mU/(L × 24h) vs. 65 mU/(L × 
24h), respectively). 
General results from the GH-dose catch-up study: 
The correlation between maximal stimulated and spontaneous GH 
concentration was weak (r=0.30, p<0.001). Classification of severe GHD, 
partial GHD and ISS is highly dependent on the method being used. Only 
looking at peak GH concentrations to assess GH levels means that important 
information from the spontaneous GH secretion pattern is missed. 
  
4.2.2 Cardiovascular findings according to degree of 
GHD or ISS – Paper II 
Table 7 gives a short summary of the characteristics of the Gothenburg population. 
Table 7. Characteristics of the Gothenburg study group. Paper II. 
Mean SD Median Min Max
Auxology 
 Age (y) 7.4 2.0 7.1 3.3 10.9 
 Height (SDS) –2.7 0.4 –2.6 –4.1 –1.9 
 Weight (SDS) –2.2 0.9 –2.2 –4.1 1.3 
Stimulated GH secretion 
 GHmaxAITT (mU/L) 18.2 9.8 16.4 3.8 44.0 
Spontaneous GH secretion 
 GHmax24h (mU/L) 23.8 11.3 23.3 2.3 58.1 
 Baseline GH level (mU/L) 0.76 0.51 0.63 0.08 2.77 
 Number of peaks 9 2 9 3 14 
 AUCb (mU/(L*24h)) 74 34 70 3 167 
GH secretion rate 
 GHb (U/24h) 0.24 0.13 0.22 0.01 0.64 
 GHt (U/24h) 0.30 0.14 0.27 0.10 0.72 
GH growth responsiveness 
 Predicted ∆height (SDS) 1.2 0.3 1.2 0.8 2.3 
Cardiovascular variables 
 Systolic BP 102 9 101 79 127 
 IVDs (mm) 5.7 0.8 5.6 4.2 7.7 
 LVPWd (mm) 4.8 0.7 4.8 3.6 7.0 
 LVDd (mm) 36.5 3.3 36.6 27.5 42.7 
 LV mass MM  (g) 48 13 45 24 80 
 LV mass MM  index (g/m2) 61 11 59 40 87 
 EF (%) 69 5 69 55 81 
 CO  MM  (l/min) 3.3 0.6 3.2 2.3 4.9 
 Mitral E/A  ratio 2.0 0.5 2.0 1.1 3.3 
 
The control population had a median age of 5.1 years compared with 7.1 years for 
the study population (p<0.001). This was as expected based on the stratification of 
the groups for height (cm). Heart rate was higher in the control group (median 92 
bpm vs. 86 bpm, respectively) and EF was lower in the control group (median 65.0 
vs. 68.7, respectively, p<0.001) than the study population. No other differences 
were found. The differences between the subgroups of short children were 
dependent on whether they were classified according to GHmax during a 
stimulation test, during spontaneous secretion or both. The only consistent finding 
was a higher EF in the children with GHD and ISS compared with controls (Table 
8). 
 Table 8. Different methods for estimating GHmax gives different results when 
comparing patient groups. 
         GHD   Controls vs. 
GHD ISS Controls ISS GHD  ISS 
Height (cm) Median      P-values      
 GHmaxAITT 111.2 112.2 111.3          
 GHmax24h 109.4 111.3 
 GHmaxAITT+24h 111.8 111.2 
BMI (kg/m2) 
 GHmaxAITT 15.6‡ 14.8 15.3 0.019 0.049
 GHmax24h 15.5‡ 15.2 0.049
 GHmaxAITT+24h 15.7‡ 15.2 0.036 
Systolic BP 
 GHmaxAITT 101 101 104 
 GHmax24h 102 99 0.032
 GHmaxAITT+24h 104 100 0.037
LV mass MM index (g/m2) 
 GHmaxAITT 56.7 63.8 58.1 0.017
 GHmax24h 58.0 59.1 
 GHmaxAITT+24h 56.8 59.3 
EF (%) 
 GHmaxAITT 69.8 65.5 65.0 0.004 <0.001
 GHmax24h 69.2 68.2 <0.001 0.004
 GHmaxAITT+24h 70.1 67.6    0.037  <0.001  0.010
 
Further sub-classification according to GHmaxAITT was done to compare with 
results from Capalbo et al. and Salerno et al.89, 90. They both found a significantly 
lower LV mass in the subgroup with severe compared with partial GHD classified 
according to GHmaxAITT. Although including a larger sample size, the difference 
in the present study was not significant (severe GHD 57.8 g/m2 vs. partial GHD 
60.5 g/m2, p=0.379). 
Classification of GHD or ISS and the heart: 
In the population of short prepubertal children, cardiac dimensions were 
similar in those children classified with severe GHD and ISS. EF (%) was 
slightly higher in the GH-deficient group compared with the ISS group, but only 
if classification was based on GHmaxAITT. No differences in cardiovascular 
structure or function were found between those with severe and partial GHD. 
  
4.2.3 GH secretion, GH growth responsiveness, 
metabolic data and the heart – Paper II 
Bivariate correlation 
Several of the GH-related and metabolic variables showed significant correlation 
with cardiac variables, selected examples are shown in Table 9. 
Table 9. Pearson bivariate correlation with selected, GH, metabolic and cardiac 
variables 
 IVSd LVDd 
LV 
mass 
MM (ln)
Auxology    
 Age 0.46*** 0.79*** 0.74*** 
 HeightSDS ns ns ns 
 WeightSDS 0.29* 0.29* 0.38*** 
Stimulated GH secretion    
 GHmaxAITT (sq) ns ns ns 
Spontaneous GH secretion    
 GHmax24h (sq) ns ns ns 
 AUCb (sq) ns ns ns 
 Baseline GH level (sq) -0.28* -0.37** -0.41***
 Number of peaks ns -0.23* -0.24* 
 Duration of peaks 0.30** 0.29** 0.32** 
GH secretion rate    
 GHb (sq) 0.30** 0.46*** 0.44*** 
 GHt (sq) 0.23* 0.39*** 0.35** 
GH growth responsiveness    
 Pred. ∆heightSDS (ln) -0.23* -0.36** -0.34** 
Metabolic data    
 IGF-I/IGFBP3 ratioSDS 0.23* 0.30** 0.30** 
 Insulin (ln) 0.27* 0.38*** 0.40*** 
*: p<0.05, **: p<0.01, ***: p<0.001 
After inserting all of the GH-related variables and metabolic variables, together 
with WeightSDS and HeightSDS, into a multiple regression analysis (Lasso method) 
with LV mass MM (ln) as the dependent variable, three variables were found to 
predict most of the variance. GHb (sq), Baseline GH levels (sq) and WeightSDS 
together had an r2 of 0.46, thus, explaining almost 50% of the variance in LV mass 
MM (ln). There were, however, high degrees of collinearity. Age, for example, 
was correlated with LV mass MM (ln) (r=0.74, p<0.001), baseline GH level (sq)  
(r= –0.47, p<0.001) and GHb (sq) (r=0.43, p<0.001).  
 
 Principal component analysis 
PCA was performed in order to help understand the network of associations 
between cardiac variables, auxology, GH secretion, GH growth responsiveness 
and metabolic data. The full rotated component matrix can be found in Paper II, 
Table 3. In brief, nine components were extracted. Figure 13 shows selected 
examples from the first two components. LVDd and LV mass were highly 
correlated with age (first component) but not at all with GH secretion as measured 
by GHmax24h or AUCt (second component). For these two dimensions, the 
baseline GH level was negatively correlated with the cardiac dimension 
component (loading of –0.42). This component was also negatively correlated 
with GH growth responsiveness (loading: –0.38), in contrast to the correlation 
with GHb (loading: 0.29). The component of LV wall thickness is shown together 
with the GH secretion component in Paper II, Figure 2, lower section.  
Figure 13. Selected variables from the component of cardiac dimensions and the 
component of GH secretion. LVDd and LV mass AL is negatively correlated with baseline 
GH level (GH trough levels) and positively correlated with GH secretion rate above the 
baseline level (GHb). 
  
There were no correlations between estimates of GH secretion and LV wall 
thickness. The GHmaxAITT had a rotated loading of –0.34 in the component of 
contractility and diastolic function but, otherwise, cardiac function was not 
correlated with different estimates of spontaneous GH secretion pattern, GH 
growth responsiveness or metabolic variables (see Paper II, Table 3 for details). 
4.2.4 Effect of gender – Paper II 
 In the study population, the girls were of a similar height (cm) to the boys 
(median 111.8 vs. 110.2, respectively, corresponding to –2.6 SDS). However, the 
girls had a lower LVDd (mm) (median 35.9 vs. 37.5, respectively, p=0.023) and a 
lower LV mass MM index (g/m2) (54.9 vs. 61.1, respectively, p=0.028) compared 
with the boys (Figure 14). In the control group, no differences were found between 
the genders. 
Figure 14. Minor gender differences in LV mass MM index (g/m2). 
 
 
Spontaneous GH secretion pattern, GH secretion rate and the heart: 
PCA analysis showed that LVDd and LV mass was negatively correlated with 
GH trough levels and positively correlated with GH secretion rate above the 
baseline level. This was confirmed by both bivariate correlation and 
multivariate regression analysis. GHmax24h was not correlated with either 
cardiac dimensions or cardiac function.  
 4.2.5 Specific effects of treatment – Paper III 
In the longitudinal part of the study, all children followed per protocol were 
described, and changes in cardiovascular variables were analyzed. Eighty-seven 
children were randomized to receive individualized treatment and 41 to receive a 
standard GH dose (doses are described in Figure 9). The original publication in the 
GH-dose trial focused on minimizing the variability in distance of current height 
from MPHSDS after 2 years of GH treatment by individualizing the dose. The range 
was reduced by 32%46. No such effect could be found for any of  the 
cardiovascular variables that were evaluated (complete data not shown, example is 
given in Figure 15). As detailed in Paper III, Table 2, most cardiovascular 
variables changed with treatment. 
Figure 15. Boxplot of change in LVDdSDS from study start to 2 years of GH treatment, 
comparing the groups receiving individualized and standard doses. No differences in 
ΔLVDdSDS or variance were found. 
The development of pathological hypertrophy was not reported during the course 
of the study. LV massSDS as measured by the MM method was +2.4 SDS after 2 
years of treatment in one child assigned to the standard GH dose group (43 
μg/kg/d). When examined 2 years later outside the study protocol, this child’s LV 
mass was at 1.7 SDS (Paper III, Figure 1). With the exception of heart rate, 
changes in cardiovascular variables (described in the Patients and methods 
section) over 2 years of GH treatment did not differ, either between the two 
treatment groups or between the children with GHD and ISS (as defined by 
GHmaxAITT). Heart rate decreased on average by 10.0 bpm in the standard dose 
group compared with 5.4 bpm in the individualized treatment group (p=0.024); 
however, due to the overall similarity between the treatment groups, data from all 
children were combined during the detailed analysis. 
  
Figure 16. Comparing the effects of GH treatment on BSA, LV mass, LV mass index and LV 
massSDS with duration of GH treatment. 
Similarly, as no important differences were found in cardiovascular effects 
between children with GHD and ISS, the two groups were combined for more 
detailed analysis. In Paper III, Figure 2, LV mass indexed to BSA, and evaluated 
both by the MM method and the AL method, had already increased after 3 months 
of treatment. After this point, there was no further increase in LV mass index. In 
Figure 16, the increases in BSA, LV mass, LV mass index and LV massSDS are 
shown as percentages of the maximum increase. The BSA increased in an almost 
linear manner by 4–5% (of the maximal change) per month (%/month). LV mass 
doubled during the first 3 months of treatment (10%/month), but later increases 
were smaller (only 3–4%/month). As a consequence, there was a dramatic increase 
in LV mass index during the first 3 months (27 %/month), followed by almost no 
further changes. The same was seen for LV massSDS.  
Figure 17 summarizes changes relative to baseline in the most important variables 
after 3 months, 1 year and 2 years. An initial decrease in diastolic BPSDS was 
observed, coupled with an increase in LV cardiac index. LVDdSDS, IVSdSDS and 
LVWPdSDS at 3 months in the absence of a change in systolic BP. At 2 years, 
IVSdSDS and LVPWdSDS had returned to baseline values, whereas LVDdSDS and 
LV cardiac index were still increased compared with baseline. Diastolic BPSDS 
remained lower than baseline and systolic BPSDS had decreased. 
 Figure 17. Changes in cardiovascular parameters during GH treatment compared with 
pretreatment values. 
 
 
 
GH treatment and the heart: 
During GH treatment there was a rapid change in cardiovascular variables. 
After 3 months, standardized measurements of cardiac dimensions had 
increased. At 1 year and 2 years, LVDdSDS remained stable, whereas IVSdSDS 
and LVPWdSDS had returned to baseline values. Reflecting a decrease in 
diastolic BPSDS, the LV cardiac index increased rapidly during the first 3 
months of treatment, thereafter remaining stable. 
  
 
4.2.6 Tissue-specific threshold for response to GH – 
Paper IV 
To study the difference in dose-dependency between different tissues, variables 
representing different organ systems were chosen. Fat massSDS, leptin, bone age, 
BMD, ALP (μkat/L), LSTSDS, heightSDS,  insulin (mU/L), IGF-ISDS, IVSd (cm), 
LVPWd (cm), LVDd (cm) and LV mass MM (g) were selected. The variables 
were analyzed as ∆ values between the start and 2 years of GH treatment. For each 
of the six dose groups, the mean ∆ was calculated (∆ dose-group mean), and is 
shown for the 87 children receiving individualized GH treatment in the per-
protocol population. When performing ANOVA and piecewise linear regression, 
substantial lipolytic effects were seen in all groups as demonstrated by changes in 
the variables fat mass and leptin from baseline to 2 years of treatment; however, 
no dose-response differences were observed between the GH-dose groups for ∆ fat 
massSDS, ∆ leptin,  ∆ bone age, ∆ BMD, ∆ IVSd or ∆ LVPWd (data not shown). 
The ∆ LV mass was found to be significant in the initial analysis (ANOVA p-
value = 0.013) and had a ED50% of 36 µg/kg/d. After excluding the small 17 
µg/kg/d group, significance was lost and these data were not included in Table 10 
(complete table shown in Paper IV, Table 1).  
Table 10. Increases in variables studied in the different dose groups. 
GH dose ΔLVDd ΔLST ΔInsulin ΔHeight Δ IGF-I 
 (µg/kg/d) (cm) (SDS) (mU/L) (SDS) (SDS) 
17 0.15 (0.10) 0.4 (0.3) 3.7 (0.7) 0.8 (0.3) 1.7 (0.2) 
33 0.35 (0.04) 0.6 (0.1) 4.8 (1.2) 0.9 (0.1) 2.0 (0.2) 
40 0.38 (0.07) 1.0 (0.1) 5.0 (1.0) 1.5 (0.2) 2.3 (0.3) 
50 0.49 (0.04) 1.1 (0.1) 6.2 (1.1) 1.4 (0.1) 2.6 (0.2) 
66 0.54 (0.05) 1.4 (0.1) 8.8 (1.4) 1.7 (0.1) 3.5 (0.2) 
100 0.50 (0.08) 1.6 (0.2) 8.8 (3.1) 2.0 (0.1) 4.3 (0.6) 
ED50% 33 47 48 51 57 
90%  Conf.bounds (24–38) (43–52) (35–65) (47–56) (52–65) 
ANOVA (p-value) <0.001 <0.001 0.012 <0.001 <0.001 
∆ Dose-group means (calculated between start and 2 years) are given (with their 
SD). Dose-group means closest to half of the dose effect (50% ∆ effect) are marked 
in bold and with light-grey boxes. The effective GH dose (ED 50%) required to 
achieve (50% ∆ effect) is calculated based on a piecewise linear regression equation 
of ∆ dose. Below the ED 50% is the corresponding 90% confidence bounds. P-
values are shown for testing a piecewise linear GH-dose effect, the ANOVA p-value 
was calculated vs. zero effect.  
 
 The variable with the lowest ED50% is the one with the highest responsiveness to 
GH treatment, indicating higher sensitivity to GH. The highest responsiveness to 
GH treatment was seen for cardiac dimensions as represented by LVDd and the 
lowest for IGF-I. Classic dose–response curves for the six different GH doses in 
the 87 children receiving individualized GH treatment are shown in Figure 18. 
Absolute dose-group means were set to 0% at study start and compared with 
values from 1 and 2 years of treatment. IGF-ISDS and LVDd at the start of 
treatment were also compared with values at 3 months of treatment. 
Figure 18. Examples of dose-response relationships. Note the different numerical values on 
the vertical axis.  
 
Tissue specific dose-response to GH treatment: 
LVDd, as a parameter of cardiac dimension, was more sensitive to GH 
treatment than markers of skeletal muscle (LST),  
longitudinal growth (height) and IGF-I. 
  
5 MAIN FINDINGS 
The relationship between endogenous GH secretion rate, secretion pattern, GH 
treatment, GH responsiveness and the heart is more complex than previously has 
been acknowledged.  
1. GH-R and IGF-I mRNA are expressed in cardiac tissue in children with 
congenital heart defects. 
2. In short prepubertal children, the GH trough level is negatively correlated 
with cardiac dimensions and GH secretion rate above baseline level is 
positively correlated with cardiac dimensions. The maximum GH 
concentrations do not correlate to cardiac dimensions. 
3. During GH treatment there is a rapid change in standardized 
measurements of cardiac dimensions with an increase in both LV wall 
thickness and diameter after three months of treatment. In the medium 
term (2 years of treatment), after fulfilled catch-up growth, LV diameter 
continues to be increased, relative to pretreatment values, but standardized 
measurements of wall thickness returns to baseline. 
4. LV dimensions are more responsive to GH treatment when compared with 
insulin, IGF-I and longitudinal growth. 
 
 
 6 DISCUSSION 
The most important contribution of this thesis is to highlight the complexity of the 
actions of GH on the heart in growing children, both in terms of the responses to 
endogenous GH secretion and to GH treatment. Our current understanding of the 
influence of the GH/IGF-I axis in the regulation of cardiovascular structure and 
function during normal conditions is limited. To expand our knowledge, we are 
confined to studies based on populations already followed within the healthcare 
system or to experimental data.  
In the adult population, the general concept is that GHD is associated with 
increased cardiovascular risk and mortality95, reduced LV mass and decreased 
cardiac output96, 97. The validity of these findings has been disputed during the last 
few years based on studies using cardiac MRI for evaluation of cardiovascular 
structure and function98. On the other side of the spectrum, GH excess, as seen in 
acromegaly, is also related to increased cardiovascular mortality and structural 
changes99. Normalization of GH levels in both GHD and acromegaly reverses 
these anomalies to some extent8. 
6.1 GH secretion and the heart 
Almost all pediatric studies, analyzing the influence of GH on the heart, have been 
conducted in children receiving GH treatment. Studies have included short 
children with and/or without a diagnosis of GHD, children with Turner syndrome, 
Noonan syndrome or muscular dystrophies, and children who have experienced 
prior anthracycline therapy, thermal injury or heart transplantation.   
Stimulation tests vs. endogenous secretion pattern 
The major part of this thesis includes short prepubertal children. In the literature, 
such children have traditionally been classified as having either GHD or ISS based 
on their maximum GH secretion levels as assessed during two GH stimulation 
tests using the arbitrary cut-off point of 10 μg/mL. The cut-off value for the 
classification of GHD has changed following the increased availability of GH48. 
This thesis has shown that the stimulated GHmax often underestimate endogenous 
GH secretion capacity, as shown in Figure 10. Moreover, in the population of 
short children, the maximum GH concentration has little relevance for 
cardiovascular structure or function. GH trough levels and the GH secretion rate 
above baseline level seem to be of greater importance; however, this information 
is not available when only using GH stimulation tests.  
  
Impact of being severely GH-deficient, partially GH-deficient or 
having ISS 
Using published data assessing the impact of impaired GH secretion or sensitivity 
on cardiovascular status, one of the major considerations  is finding an appropriate 
control population. If matched for age or height, normal controls will be taller or 
younger, respectively, than the short population. Two of the six available studies 
in the literature included children of varying pubertal status. The control groups 
either differed from the study population in terms of body size or data on body size  
were not reported. This unfortunately precluded the drawing of valid conclusions 
regarding the pretreatment cardiovascular status of the short children in these 
studies100, 101. In a more recent study by Lanes et al., 12 short untreated children 
with GHD were compared with 14 controls, all of varying pubertal status, but with 
similar average absolute height102. They found no differences in LV thickness 
between the groups. LV diameters were not reported but both diastolic and systolic 
volumes were lower in the GH-deficient population than in controls. This was also 
true for LV mass indexed to BSA. It should be noted that three of the 12 short 
children had brain tumors as the etiology of their GHD, and four of the children 
had been previously treated with GH. The three remaining studies are from the 
Italian group which has published several papers on GH and the heart, both in 
adults and children89, 90, 103. In their reports, all children were prepubertal. In the 
first study by Salerno et al., 12 short children (one of which had a brain tumor) 
classified as GH-deficient based on two stimulation tests were compared with 12 
controls matched for height and BMI. Neither the age nor heightSDS of the control 
population were reported103. They found IVSd to be similar in both groups, but 
both LVPWd and LVDd were smaller in the GH-deficient population than in 
controls. As a result, the population with GHD had a smaller LV mass index than 
controls. Variables of systolic function were similar in both groups. The next study 
from the Italian group was published in 2006, and most likely included the same 
12 patients plus another 18 GH-deficient children (not disclosed in the article)90. 
The GH-deficient population was on average 9.3 years and the control population 
9.8 years. Unfortunately, they did not report absolute height, but the control 
population had an average heightSDS of –1.5 SDS with an SD of 1.1. If height were 
indeed normally distributed as claimed, a significant number of the 30 controls 
actually had a heightSDS <2.0 and most likely could be considered to have ISS. 
They found no difference in heart rate or BP between groups. IVSd was similar in 
both groups but LVPWd was reduced in the GH-deficient  group relative to 
controls. As in the previous study, LVDd was smaller in the group with GHD and, 
as a consequence, LV mass index was reduced compared with controls. As in their 
previous publication, no differences were found, neither in systolic nor diastolic 
function compared to controls. More interestingly, when subdividing the patients 
into those with severe and partial GHD based on the GHmax during stimulation 
tests. They found that LVPWd (but not IVSd), LVDd and LV mass index were 
reduced in the group with severe GHD relative to those with partial GHD. The 
 most recent study comparing short children and children of normal stature was 
published in 200989. This study included 24 GH-deficient children (based on 
stimulation tests) and compared them with younger children of equal stature. The 
average heightSDS of the controls was –1.2, resulting in a significant number being 
less than –2 SDS in height. In this study, they were able to demonstrate lower 
IVSd, LVPWd, LVDd, LVDs and LV mass index in the GH-deficient group 
compared with controls. They also found subtle reductions in systolic function, as 
estimated by mVCFc, ESS and SSI. Moreover, they repeated their previous 
finding, showing a dramatic difference in cardiac parameters between children 
classified as having severe and partial GHD. These differences between GH-
deficient children and controls were not confirmed in the present thesis, either 
when classified according to the GHmax during a stimulation test or according to 
the endogenous GH secretion. The control group in this thesis was of a similar 
height to the group investigated in the later study, and had normal heightSDS, 
resulting in their age being almost 2 years younger than the controls in the Italian 
study. The short population in the thesis was also on average 1 year younger then 
the Italian study-population, which suggests a shorter duration of GHD, which 
may explain the differences found. No important differences between children 
classified as having severe or partial GHD were found in the present thesis, 
something that was clearly demonstrated by both Salerno et al. and Capalbo et 
al.89, 90. This discrepancy is more difficult to explain. Including more children and 
using the same methodology as the Italian studies, the present study should have 
had greater power to detect any significant differences between partial and severe 
GHD. Again, there was a difference in ages. This may indicate that age has an 
impact of cardiac dimensions that is unrelated to body size. In the present thesis, 
only children with isolated GHD were reported upon, resulting in few children 
being severely GHD. This may need to be taken into account when comparing the 
publications.  
Comparison of pretreatment data in short children with normal GH secretion and 
controls has not been previously reported on. The differences found were minor 
and dependent on whether a GH stimulation test or a test of spontaneous GH 
secretion was used. Before drawing any conclusions, larger studies comparing 
cardiovascular findings in children with ISS and control populations are needed. 
Importance of GH secretion pattern 
No previous study has investigated the association between estimation of 
endogenous GH secretion pattern and cardiovascular dimensions or function. Both 
in the validated multivariate analysis, and in the PCA, trough GH levels, were 
negatively correlated with LV mass and LV diameter in diastole. This indicates 
that children with higher baseline GH level have a lower LV mass or smaller LV 
diameter. Interestingly, some data indicates that children born small for gestational 
age (SGA) have increased GH trough levels104, and a recent study has shown that 
  
these children have a lower LV diameter in diastole compared to reference 
values105. Biological importance of elevated GH trough levels are also supported 
by experimental studies106. More human studies are needed to confirm the 
relationship between GH trough levels and LV dimensions. 
Spontaneous GH secretion pattern has distinct effects on different 
cardiac dimensions 
Another interesting finding in this thesis was that the impact of GH secretion 
pattern on the heart differed for LV diameter and wall thickness. The GH trough 
levels and the GH secretion rate above baseline values were inversely related to 
LVDd but showed no relationship to LV wall thickness. This is in line with a 
study by Andreasen et al. which used cardiac MRI to compare adults with GHD 
and controls98. They found reduced LV diastolic volume but not LV mass in the 
GH-deficient population. Increased diastolic volume in the absence of an increased 
mass most likely corresponds to an increased diameter but equal wall thickness. 
 
6.2 GH treatment and the heart 
GH treatment affects the heart in a differentiated and time-
dependent manner 
A differentiated response to GH treatment was seen in the present study. Initially 
there was a rapid response to GH, with an increase in standardized measurements 
of LV wall thickness, diameter and mass after 3 months. However, after 2 years of 
treatment, LV wall thickness had returned to baseline values, whereas LV 
diameter and mass remained increased. The mechanism underlying this response is 
yet to be determined, but possible explanations include both direct effects of GH 
and IGF-I on sodium retention and cardiac tissue. Johannsson et al. showed that 
GH secretion and heart: 
All studies comparing cardiovascular variables in short children with  
"normal children" have the problem of defining a suitable control population. 
In a cohort of equally short children, the actual peak GH concentration has 
little impact on cardiovascular structure and function. Interestingly, other 
aspects of the GH secretion pattern, like GH trough levels, seem to be of 
greater importance. Higher GH trough levels are correlated to lower LV mass 
and LVDd. Measurements of the actual wall thickness seem to be dissociated 
from GH secretion. This appears to be in line with detailed  
studies on adult populations. 
 short-term GH treatment in adults was associated with renal sodium retention and 
increased extracellular water (ECW)107. In their study, renal sodium secretion 
returned to pretreatment values after 1 year of treatment but ECW remained 
elevated. In another short-term study by Møller et al., plasma volume was shown 
to be unchanged108. In children, the effect on sodium and fluid homeostasis seems 
to be of shorter duration. Lampit et al. showed that the increase in sodium and 
water retention were normalized after 7 and 28 days of GH treatment, 
respectively109. As there is limited information about fluid and sodium 
homeostasis after 3 months of GH treatment in children it is difficult to know 
whether sodium and fluid retention alone can explain the increase in LV wall 
thickness found at this time point. As plasma volume seems to be unchanged, it is 
unlikely to affect LV diameter. To understand the mechanism responsible for the 
change in cardiac dimensions, other hemodynamic alterations have to be taken 
into account. At the 3-month examination, standardized measurements of diastolic 
BP was reduced in parallel with an increase in cardiac index. This could be 
explained by reduced peripheral vascular resistance and could be the mechanism 
responsible for the increased standardized LV diameter in diastole seen at 3 
months. However, as the standardized systolic BP was unchanged, this does not 
explain the increase in myocardial thickness. In animal studies, GH has been 
shown to be involved in cardiac gene expression and collagen deposition in 
extracellular matrix8. In this thesis, GH-R mRNA and IGF-I mRNA were 
expressed in cardiac biopsies from children. The early increase in septal and 
posterior wall thickness could be influenced by direct effects of GH on the heart. 
Interestingly, at 2 years, the effect on LV diameter, diastolic BP and cardiac index 
remained, but standardized measurements of myocardial thickness returned to 
baseline values. This may be a consequence of the reduced systolic BP seen at 2 
years, although other mechanisms cannot be excluded. 
With individualized dosing, children with GHD and ISS respond 
similarly to GH treatment 
With the dose of GH being individualized to meet the estimated demand, no 
difference in the response to GH treatment was found when comparing children 
classified as GH-deficient with those classified as having ISS. This is the first time 
that data from short children with the complete range of GH secretion have been 
analyzed together. Previous studies in the literature on the cardiac effects of GH 
treatment have been confined either to the GH-deficient population or the 
population with ISS. This is also the first time that the cardiovascular effects of 
doses as high as 100 µg/kg/d have been examined. Table 11 and 12, summarizes 
previous studies on short children without Noonan or Turner syndromes. None of 
the studies report any adverse cardiovascular events due to GH treatment, even 
though long-term follow-up is lacking. 
  
Cross-sectional studies on GH treatment and the heart in short 
children 
There are four cross sectional studies and nine longitudinal studies regarding GH 
treatment available in the literature (Table 11).  
Table 11. Cross-sectional studies on cardiovascular data  in GH-treated children 
and adolescents compared with untreated controls of normal height. 
Year Author 
Ages
years Class Pts Cont. 
Dose 
µg/kg/d
Dur.
years BP
LV
wall
LVD/ 
Vd 
LV 
mass 
index 
Sys 
fx 
Dias 
fx 
1991 Rowland9 5–17.7 
GHD 
& 
ISS 
16 Ref. 14–30 2.1  ↔ ↔  ↔  
1995 Crepaz16 3–17 GHD 22 22 33–56 1.2 ↔  ↔ ↔ ↔ ↔ 
2000 Stamoyannou110 4.4–16.8 GHD 42 34 33±15 2.9 ↔  ↔ ↔ ↔  
2005 Lanes102 14.6 ±1.7 GHD 10 14 33 3.8  ↔ ↓ ↓ ↔  
↔ indicates no change compared with untreated controls without GHD, ↓ indicates decreased values 
compared with controls. Values are presented either as mean ± SD or range. Doses were presented 
differently in the different articles and were recalculated to approximate µg/kg/d for comparison. 
Abbreviations confined to this table: Dias fx: diastolic function, Dur: duration, Class: classification, Cont: 
controls, LVD/Vd: left ventricular diameter or volume in diastole, Pts: patients, Ref: reference population, 
Sys fx: systolic function. 
 
In the four available cross-sectional studies on GH-treated short children, a total of 
90 GH-deficient children and 3 children with ISS that had been on treatment for 
on average 1.2–3.8 years were compared to either controls without GHD or 
reference data (one study)9, 16, 102, 110. For comparison with this thesis, the doses 
were recalculated into corresponding approximate µg/kg/d and ranged from 14 to 
56 µg/kg/d. Where reported upon, blood pressure, wall thickness, systolic and 
diastolic function was similar in treated children and adolescents compared to 
controls. Only in one study, the LV diastolic volume and LV mass index was 
reduced in the treated group compared to controls without GHD. The most valid 
interpretation of this data is that GH treatment in average does not result in cardiac 
dimensions or function different from the normal population. 
Longitudinal studies on GH treatment and the heart in short 
children 
The first of the longitudinal studies was performed on children classified as having 
ISS. It was initially published by Barton et al. as a preliminary report in 1992 and 
subsequently as a full paper in 199511, 12. Compared with pretreatment values, the 
LV mass index increased only in the group given a higher GH dose 
 (approximately 67 µg/kg/d). An additional eight longitudinal studies have 
previously been published (Table 12)10-12, 15, 17, 89, 90, 103, 111, 112.  
Table 12.  Longitudinal studies in short GH-treated children and adolescents. 
Changes in cardiovascular variables during treatment. 
Year Author 
Age 
years Pts Class
Dose 
µg/kg/d
Dur.
years SBP DBP
LV 
wall LVDd
LV 
mass 
Index 
Sys 
fx 
Dias 
fx 
1995 Barton12 5–10 29 ISS 36/72 2 ↔  ↔  ↑ ↔  
1995 Daubeney15 8 ± 0.5 15 ISS 54 4 ↔ ↑ ↔ ↑ ↔ ↔  
1998 Lampit10 5 ± 1 21 ISS 34 3    ↔  ↔  
1999 Radetti17 5–17 14 GHD 34–55 5.5 ↔ ↓   ↑   
2003 Shulman112 4–12 10 GHD 43 1 ↔    ↑ ↔ ↔ 
2004 Salerno103 6–11 12 GHD 30 1 ↔ ↓ ↑ ↑ ↑ ↔ ↔ 
2006 Salerno90 6–12 30 GHD 30 2 ↑ ↓ ↑ ↑ ↑ ↔ ↔ 
2009 Capalbo89 4–13 24 GHD 30 2 ↔ ↔ ↑ ↑ ↑ ↑ ↔ 
2011 Ozdemir111 11 ± 3 12 GHD 25 0.5   ↔ ↑ ↑ ↔ ↓ 
2012 Nygren Paper II 3–11 127
GHD
ISS 
17–  
100 2 ↓ ↓ ↔ ↑ ↑ ↔ ↔ 
↔ indicates no change,  ↓ indicates decreased values and ↑ indicates increased values at last examination 
compared with pretreatment measurements. Values are presented either as mean ± SD or range. Doses were 
presented differently in the different articles and were recalculated to approximate µg/kg/d for comparison. 
 
The most consistent finding was that of increased LV mass index and LVDd. 
There seems to be a larger discrepancy in earlier studies in populations with ISS10, 
12, 15. The three most well designed studies from the Italian group all show an 
increase in LV dimensions following treatment from subnormal values at baseline, 
and Capalbo et al. show restoration of slightly impaired contractility89, 90, 103. 
Tissue-specific dose-response 
This thesis also supports the existence of differential responsiveness to GH 
treatment among different organ systems. Of the variables studied, LV dimensions 
appeared to be the most sensitive to GH. Based on the results in Paper IV, a 
staircase model has been proposed  (examples in Figure 19). The hypothesis of the 
main GH-dose catch-up study was to examine whether the highly variable 
response usually seen during GH treatment could be reduced by individualizing 
the dose. This was done using a validated model predicting growth in response to a 
standard GH dose of 33 µg/kg/d. The dose was then optimized so that the child 
would end up as close as possible to MPH after 2 years of treatment (i.e. children 
predicted to end up above MPHSDS had their dose lowered, and children predicted 
not to reach MPHSDS on the standard dose had their dose increased). This resulted 
in a 32% reduction in variability in distance to MPHSDS after 2 years of treatment 
as predicted in this hypothesis generating study46. 
  
 
Figure 19. The staircase model of tissue sensitivity. Variables with a low dose predicted to 
result in 50% increase (ED50%) are more responsive to GH treatment than variables with 
a high ED50% . The gray area shows the 90% confidence bounds.  
Reduced variability of response with individualized treatment has also been found 
for insulin113 and behaviour problems114. Reduced variability for LV wall 
thickness, LV diameter or LV mass was not found in this study. This is not 
surprising considering the higher GH responsiveness of the heart. With an ED50% 
for change in LV diameter as low as 32 µg/kg/d, the dose selection process was 
not optimized to reduce the variability in cardiovascular response. 
GH treatment and the heart in short children: 
Cardiac dimensions increased during GH treatment. Initially there was an 
increase in both standardized measurements of LV diameter and wall 
thickness, but after 2 years of treatment, only LV diameter stayed increased 
relative to pretreatment values. Most studies, including ours, indicate that GH 
does not result in pathological hypertrophy or impaired cardiac function. The 
longest longitudinal follow up was for 5.5 years and the  
highest GH dose used was 100 µg/kg/d. 
 6.3 GH in pediatric heart disease 
6.3.1 GH secretion in congenital heart disease 
In late sixties and seventies, several studies examined GH secretion in congenital 
heart disease115-118. In brief, surprisingly high peak GH concentrations were found 
together with low IGF-I levels. GH levels increased after cardiac catheterization119 
and in response to heart surgery120. Interestingly, if cardiac disease was 
compensated (i.e. without significant hemodynamic compromise), GH levels were 
normal121. These studies indicated that uncompensated heart disease and trauma 
related to cardiac surgery both are associated with increased peripheral resistance 
to GH. Moreover Pons Leite et al. showed that prolonged elevation of GH levels 
was associated with a poorer outcome after heart surgery122. Later studies have 
even shown that the severity of congenital heart defects (shunt size, 
cyanotic/acyanotic) also influenced GH and IGF-I levels as an indicator of 
peripheral resistance123-125. Although cyanotic heart defects in particular are 
associated with poor growth, cardiac surgery results in increased IGF-I, increased 
growth velocity and increased BMI126. More recent interest in GH secretagogues 
has also resulted in a publication showing increased ghrelin levels in both cyanotic 
and acyanotic heart disease, as well as a relationship between ghrelin and impaired 
BMI127. In conclusion, heart defects in children are most likely associated with 
peripheral resistance to GH resulting in impaired growth. Fortunately, correction 
of the heart defect normally results in reversal of GH insensitivity and improved 
growth. Sasaki et al. studied seven children in whom growth retardation persisted 
2 years after correction of their heart defect128. GH treatment with approximately 
25 µg/kg/d resulted in improved longitudinal growth without any reported adverse 
events. 
 
 
GH and congenital heart disease: 
Congenital heart disease and surgical trauma are associated with signs of 
increased peripheral resistance to GH (i.e. high GH levels and low  
IGF-I levels). This is often seen in parallel with impaired statural growth. 
Correction of the heart defect usually results in reversal of GH  
resistance and improved growth. 
  
6.3.2 GH treatment of heart failure 
Dilated cardiomyopathy 
Observation of increased cardiomyocyte hypertrophy129, improved contractility 
through increased myofilament sensitivity to calcium29, and regulation of 
apoptosis130 has evoked interest in using GH in the treatment of heart failure of 
various etiologies. McElhinney et al treated eight children with dilated 
cardiomyopathy with approximately 25 to 40 µg/kg/d for six months in a cross 
over study131. Although not reaching statistical significance, EF showed a trend 
towards increase during GH treatment. Treatment was concluded to have a good 
safety profile, but LV dysfunction progressed in two children and they were 
transplanted during the trial. Rosti et al. described a case of a 6- month-old girl 
with a complex univentricular heart and dilated cardiomyopathy treated with 0,1 
IU/kg/d (33 µg/kg/d) of GH for 3 months132. Parents reported an increased 
exercise tolerance but no echocardiographic improvement could be seen. Ikemoto 
reported beneficial effects of GH treatment in an infant with dilated 
cardiomyopathy receiving a dose of 0.2 IU/kg/w every other day (corresponding to 
approximately 9 µg/kg/d)133. 
Muscular dystrophies 
Cittadini et al. reported on six children with Duchenne muscular dystrophy and 10 
adults with Becker muscular dystrophy with signs of cardiac involvement134. The 
six children were randomized to receive either 33 µg/kg/d of GH or placebo for 3 
months. NT-proBNP as a biochemical marker of heart failure decreased in the 
GH-treated group (including the adult patients). The small number of children 
(three in each group) precluded any valid statistical analysis, but the authors noted 
a 29% increase in LV mass and 33% decrease in end-systolic stress in children 
receiving GH treatment. 
Post anthracycline therapy 
Anthracycline treated cancer survivors have a high prevalence of decreased 
cardiac function and reduced LV dimensions. Lipshultz et al compared 34 
anthracycline treated children with 86 controls in a retrospective fashion135. GH 
given two to seven times a week at a dose of 29 to 57 µg/kg/d for a median time of 
3.8 years. LV wall thickness was reduced in the anthracycline-treated children and 
improved during GH treatment. Shortly after stopping treatment, this effect was 
lost and GH treatment was concluded not to affect progressive LV dysfunction in 
this population. Studying survival in young adults after acute lymphatic leukemia 
in childhood, Follin et al. found no difference in LV systolic function between 16 
patients treated with GH for 5 years and 13 patients who did not have GH 
treatment136. In a previous report on 2-year data from the same population, there 
was a significant improvement in LV mass index and EF in those who were GH-
treated137. 
 GH treatment of heart failure in adults 
Le Corvosier et al. published a meta analysis in 2007 of studies of GH treatment in 
adults with heart failure, highlighting variability in results between papers138. 
Merging the data, they found several cardiovascular benefits of GH doses 
(approximately 5 to 20 µg/kg/d). LV wall thickness increased, diameter decreased, 
EF improved, systemic vascular resistance decreased, New York Heart 
Association (NYHA) classification increased, exercise duration and VO2max 
increased. Despite this compelling evidence of the efficiency of GH treatment in 
heart failure, no large-scale randomized, placebo-controlled studies have been 
performed with hard end-points like cardiovascular-related mortality. 
 
6.4 GH treatment in other conditions 
Turner syndrome 
Turner syndrome is caused by the absence of genes from the short arm of one the 
X chromosomes in girls, ranging from monosomy X to different mosaic 
karyotypes. Turner syndrome is associated with ovarian failure and short stature. 
The short stature is partly caused by changed proportions of different isoforms of 
GH20, 139. Girls with Turner syndrome also have a high prevalence of heart defects. 
Heart defects were found in about one-third of a series of sixty girls with Turner 
syndrome from our institution (unpublished data). The most common defect was 
bicuspid aortic valves, which are known to predispose for later aortic stenosis, 
insufficiency and aortic dilation140. There was also a high prevalence of aortic 
stenosis and coarctation of the aorta. LV mass and LV diameter were not altered in 
GH-treated compared with non-GH-treated girls. In a larger study by Sas et al., 62 
girls treated with randomly assigned GH doses, ranging from 45 to 90 µg/kg/d, 
were followed for 7 years13. Pretreatment diastolic BP was elevated but decreased 
with duration of treatment. LV wall thickness and LV diameter also decreased 
with time. Compared with reference values, there were no differences between the 
different dose groups. Radetti et al. published a cross-sectional study in 2001 
comparing 26 girls with Turner syndrome treated for an average of 5 years (dose: 
GH treatment in heart failure: 
Data on the effectiveness and safety of GH treatment in pediatric  
heart failure are limited. There are some evidence of increased LV mass and 
improved contractility, but these results need to be studied further. In adult 
heart failure, the evidence in favor of using GH is increasing,  
but large scale studies are so far missing. 
  
1 U/kg/w corresponding to approximately 47 µg/kg/d) with 37 controls matched 
for age and body size141. They found a lower LV volume in systole, lower 
systemic vascular resistance, lower E/A ratio, increased mVCFc, higher systolic 
BP and lower diastolic BP in the GH-treated group. They interpreted these results 
as reflecting an increased contractile state and signs of impairment in diastolic 
function, secondary to a GH-induced decrease in peripheral resistance and increase 
in heart rate in the GH-treated girls with Turner syndrome. Matura retrospectively 
reviewed 67 GH-treated and 19 non-GH-treated girls with Turner syndrome and 
found no differences in cardiac dimensions or systolic function142. Bondy et al. 
focused on the impact of GH treatment on aortic dimensions143. They compared 53 
GH-treated girls (average duration 5 years) with 48 non-GH-treated girls. The GH-
treated group was taller and had larger aortic dimensions than the non-GH-treated 
group, but in a multivariate analysis neither history of GH treatment nor duration 
of treatment were related to larger descending aortic diameter. Although not a 
pediatric study, van den Berg et al. found no cases of myocardial hypertrophy, 
well preserved systolic function, higher heart rate and smaller ventricular volumes 
in young adult women with Turner syndrome compared with controls144. The 
patients had discontinued GH treatment for at least 6 months when examined by 
cardiac MRI. 
Noonan syndrome 
Noonan syndrome is characterized by facial dysmorphism, short stature and 
cardiac defects, most commonly pulmonary valve stenosis and hypertrophic 
cardiomyopathy. Final height is improved by GH treatment and so this therapy is 
currently being used more frequently in this population145. Cardiovascular effects 
of GH in Noonan syndrome have been addressed in five papers reporting on two 
trials. Cotterill et al. studied 27 children treated with 4 IU/m2/d (approximately 50 
µg/kg/d of GH for 3 years. These children were compared with untreated patients 
with Noonan syndrome. The study included children with heart defects, but 
required septal thickness to be no more than 1 cm146. The first paper, reporting 1-
year data, showed increased LV diameter in diastole in GH-treated children but 
otherwise no differences relative to non-GH-treated patients. The second study 
reported on 3-year data and no cases of ventricular hypertrophy were found in GH-
treated patients147. The following year, the subset of patients with heart defects, 
from the same trial, were analysed, still without showing any development of 
ventricular hypertrophy148. Noordam et al. reported on 27 children followed for 3 
years, and 19 children with heart defects followed for 5 years (one child was found 
to have mild hypertrophic cardiomyopathy at pretreatment examination)149. They 
found no differences in echocardiographic parameters compared with controls, and 
LV wall thickness did not change in the group followed until the end of 
treatment150. These data are reassuring in terms of safety. However, not believed to 
be related to GH treatment, there have been some reports of cardiac adverse events 
from the Kabi International Growth Study (KIGS) database. Of 429 GH-treated 
 children with Noonan syndrome, three had cardiac arrhythmias, one had severe 
LV hypertrophy and one had non-defined cardiomyopathy leading to heart 
transplant151.  
Post heart transplantation 
Mital et al. monitored longitudinal GH treatment in ten children following heart 
transplant (dose: 43 µg/kg/d for an average of 2.5 years)152. During treatment, FS, 
LV mass index, LV volume in diastole and LV cardiac index increased. 
Discontinuing treatment resulted in echocardiographic variables returning to 
pretreatment values, with the exception of LV volume which remained increased. 
No increase in rate of transplant rejection was seen, and GH treatment was 
considered to have a good safety profile.  
Post thermal injury 
Severe burn injury is associated with muscle protein catabolism for at least 9 
months after the accident and growth delay for up to 2 years153, 154. Mlcak et al. 
have published a randomized, placebo-controlled study on GH treatment in 
children with severe burns155. They randomized 76 severely burned children to 
receive either daily injection of either saline or GH (dose 50 µg/kg/d) for 1 year. 
They found an increase in EF from 63 to 69% in the GH-treated group. There were 
no other differences in cardiovascular variables. GH treatment in severely burnt 
children was concluded to have a good safety profile and to be beneficial for the 
heart. 
Growth hormone and arrhythmias 
In adult GH overproduction, concerns have been raised about an increased risk of 
ventricular arrhythmias because of the increased incidence of late potentials on 
signal averaged ECG156. There is, however, upcoming evidence that short-term 
GH treatment might protect against arrhythmias secondary to experimental 
myocardial infarction in rats157, 158. This has also been found for ghrelin159. 
GH treatment in other conditions: 
GH has been used to treat short stature in different subpopulations of children 
including those with Turner syndrome and Noonan syndrome, as well as in 
children after heart transplant. GH has also been used in the catabolic state 
after burn injury and in experimental studies on ventricular arrhythmias. 
Although results are not consistent, there is evidence of improved contractility 
and reduced ventricular arrhythmias, without any major safety concerns. 
Children with Noonan syndrome receiving GH treatment should, however, be 
monitored closely because the natural history of the condition includes an 
increased prevalence of hypertrophic cardiomyopathy.  
  
6.5 Potential risks with GH treatment 
In January 2012 Carel et al. published the data that one year earlier had concerned 
regulatory authorities and endocrinologists160. From the French population in the 
Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) 
study, they showed that mortality was higher in young adults treated with 
recombinant human GH as children compared to the general population, especially 
so in those treated with higher doses (> 50 µg/kg/d, mainly children born SGA). 
For example, the 95% CI of the standardized mortality ratio (SMR) was 1.01–
14.63 for bone tumors, 1.40–5.83 for cardiovascular causes and 1.79–17.05 for 
subarachnoid or intracerebral hemorrhage. In the same issue of The Journal of 
Clinical Endocrinology and Metabolism, a detailed study of causes of death in the 
Belgian, Dutch and Swedish cohorts from the SAGhE study was published161. Of 
the 21 deaths identified, 12 were accidents, four were suicides, and one each was 
due to pneumonia, endocrine dysfunction, primary cardiomyopathy, deficiency of 
humoral immunity and coagulation defect. None died of bone tumors or 
intracerebral hemorrhage. The patient who died of primary cardiomyopathy was 
19.1 years old and had been on GH for 1.9 years with an average dose of 33 
µg/kg/d. He had a GH-treated sibling who also died of cardiomyopathy (the 
sibling lived in the UK and was therefore not included in the article, personal 
communication Dr Sävendahl). Albertsson-Wikland et al. have developed a novel 
mortality model for the general population Swedish population. This model was 
applied to 3 854 children with isolated GHD, ISS or SGA treated with GH for a 
total of 44 894 patient-years162. In addition to using only age, gender and calendar 
year, as in SMR, the model also include birth variables (birth weight, birth height 
and gestational age), concomitant cardiovascular disorders, other malformations 
and interactions with age. Twenty one deaths were observed in the studied 
population and the model predicted 22.01, giving a hazard ration not different to 
the general population. This indicates that the increased mortality seen in the GH 
treated population most likely is not caused by the GH treatment in itself.  
Takala et al. observed increased mortality in critically ill adult patients treated with 
high GH doses (70–130 µg/kg/d)163. In two prospective randomized double-blind, 
placebo controlled studies, they found the 95% CI of the relative risk of death for 
those receiving GH to be 1.3–2.9, and 1.6–3.5, respectively. The reason for the 
increased mortality in these studies is not entirely clear164.  
A few case reports on possible cardiovascular adverse events associated with GH 
treatment have been published. Kobayashi et al. reported a possible connection 
between the worsening of hypertrophic cardiomyopathy and GH treatment165. 
Grattan and McCrindle reported a child with a univentricular heart and Fontan 
circulation who had recurrent exacerbations of protein losing enteropathy during 
GH treatment. This was thought to be caused by the aldosterone antagonistic 
 effects of GH166. In addition, there has been a case report of a child undergoing 
GH treatment for short stature who developed complete heart block. The authors 
discuss the possibility that the heart block was caused by GH treatment167. 
 
6.6 Conclusion 
Regulation of the cardiovascular system by GH is complex. This is  especially the 
case in growing children. Previous studies have focused on the importance of 
associations between maximum GH levels obtained following GH stimulation 
tests and different cardiovascular variables of interest. By analyzing the 
spontaneous GH secretion pattern as well as rate, inverse effects of the GH trough 
levels between peaks and the GH secretion rate above baseline level was 
demonstrated. There was also a difference in the actions of GH on LV diameter 
and LV wall thickness. This translated into an effect during GH treatment, where 
LV diameter and wall thickness behaved differently in response to treatment in a 
time-dependent manner. Initially, there was an increase in both standardized 
measurements of LV diameter and wall thickness, but with time LV wall thickness 
returned to baseline values and LV diameter remained increased. This highlights 
the importance of not placing too much focus on LV mass, which is generally 
derived based on a calculation from LV diameter and wall thickness. Based on the 
present studies and the literature, GH treatment in children appears to have a good 
safety profile, despite recent concerns about increased mortality in adults 
previously treated with GH. The development of hypertrophic cardiomyopathy as 
a result of GH treatment seems unlikely, but subpopulations with a predisposition 
for the disease should be followed closely. 
Currently available information should be interpreted with caution. Studies in the 
literature include relatively few patients and employ different inclusion criteria 
and a wide range of GH doses, making it difficult to draw firm conclusions. The 
presence of GH-R and IGF-I mRNA in cardiac tissue, however, indicates that the 
heart is a primary target organ for GH. 
Safety of GH treatment: 
Available data so far indicate that GH treatment in children has a  
good safety profile. This is true both for the heart and for other organ systems. 
Care should, however, be taken when treating special subgroups of patients: 
children with Noonan syndrome, children with severe hemodynamic 
compromise and children with complex cardiac lesions. 
  
7 FUTURE PERSPECTIVES 
This thesis is only scraping the surface of the complex hormonal regulation of 
cardiovascular structure and function. Basic knowledge about how the heart grows 
during different periods in life is limited. What are the growth velocities of cardiac 
dimensions during infancy, childhood, juvenility, puberty and adulthood? Can 
future problems in hereditary disorders be predicted by studying this pattern in an 
individual patient? What parts of the endogenous GH secretion pattern are of 
importance during the different phases of growth, and how does GH interact with 
sex steroids and other hormones in the regulation of cardiac dimensions and 
function? 
In the light of emerging evidence that GH doses need to be individualized based 
on predicted longitudinal growth responses, it is likely that average GH doses 
given to children will increase in future. It will, therefore, be important to continue 
to monitor the cardiovascular safety of GH treatment in patients with different 
conditions who receive this therapy.  
Studies on the impact of GH treatment for short stature in congenital heart disease 
are few and need to be expanded. Is there a way of predicting which children will 
not experience catch-up growth after cardiac surgery, and what is the best way of 
managing them? 
The most interesting perspective for a cardiologist is the possibility of using GH in 
the treatment of myocardial dysfunction. The preparation of these protocols will 
most likely be complex, and the results of clinical trials will be difficult to predict. 
This is particularly the case because of the apparent discrepancy between the 
effects of GH on the heart in patients with poor ventricular function and in short 
children with normal ventricular function. LV diameter increases in GH-treated 
short children and decreases in adults with heart failure. LV wall thickness is 
virtually unchanged in short children during GH treatment and increased when 
treating patients with heart failure. There is also a concern regarding the 
population with univentricular heart defects and a, so called, Fontan circulation, 
where caution must be taken to avoid side effects because of fluid retention. 
Optimal dosing is to be determined. 
One emerging field that may reach the hospital floor in 5 to 10 years, is the use of 
GH in the treatment of ventricular dysrhythmias. With today's anti-arrhythmic 
drugs having significant side effects and potential adverse impact on systolic 
function, GH might become an important therapeutic addition, especially for 
short-term treatment. 
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